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ABSTRACT
Infectious diseases still contribute to significant morbidity and 
mortality in many countries around the world, which includes 
Malaysia. Human viruses are among the important causative 
pathogens that pose serious threats to the world population. It has 
been demonstrated in over the past centuries that viruses can kill 
millions through outbreaks, especially infections that involve the 
respiratory system, such as the influenza pandemic and SARS 
coronavirus outbreak. These kinds of infections can spread rapidly 
across the world. Malaysia has had its fair share of fatal outbreaks 
such as the enterovirus 71 and Nipah virus outbreaks. Four 
important issues will be highlighted in this paper: the molecular 
epidemiology of respiratory viruses, prevention of the hand-foot-
and-mouth disease, beyond childhood hepatitis B immunisation 
and adult immunisation. Respiratory viruses are the cause of the 
most common infections among humans. The vast majority of the 
infections are asymptomatic and mild in nature, and they are also 
mostly self-limiting. Molecular methods offer increased sensitivity 
and specificity in detecting these respiratory viruses. Such methods 
can also be used to detect other uncommon but important viruses. 
Molecular epidemiology is a useful and increasingly valuable tool. It 
can be used to explain viral evolution, its geographical transmission 
and hospital infection transmission. From these data, we can design 
strategies and interventions to counteract and prevent infections. 
The use of single interfering RNA as an anti-RSV agent will also 
be highlighted. Hand-foot-and-mouth disease used to be a mild and 
self-limiting childhood disease, but in recent years an increasing 
number of deaths have been reported due to complications 
involving the central nervous system particularly involving the 
related enterovirus 71. This clearly shows that the virus has evolved 
and mutated and increased in pathogenicity. To counteract such 
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infections, in addition to maintaining a high level of hygiene, 
an effective vaccine against the virus is also badly needed. The 
development of a vaccine for the enterovirus 71 will be highlighted, 
where it shows good potential, through the use of a combination 
of inter-buccal and intra-dermal routes, to achieve maximum 
protection. This combination was shown to elicit the production of 
both IgA and IgG. Further, the childhood hepatitis B immunisation 
program has been successful in reducing the prevalence of hepatitis 
B and hepatocellular carcinoma in Malaysia. However, beyond 
this childhood programme, we are now increasingly facing the 
issue of hepatitis B virus mutants and occult hepatitis B infections. 
This poses a threat of transmissions, particularly during blood 
transfusion and also organ transplants. What is worrying is that 
this condition has been found to occur more among vaccinees 
than unvaccinated individuals. The impact of these mutants and 
occult infections is also explored. Adult immunisation is thus of 
growing concern particularly because of its low uptake despite the 
availability of effective vaccines. Adults need to be vaccinated just 
like children as the effectiveness of childhood vaccines wanes with 
aging. Majority of adults, particularly the elderly, have increasing 
morbidity due to the onset of chronic diseases and thus it is vital 
for them to get themselves protected via immunisation. Health care 
professionals should also be immunised against specific diseases 
to protect themselves and to prevent transmission to their patients. 
Unfortunately, the uptake of such has been inconsistent, and thus 
strategies and interventions should be carried out to remedy the 
situation. We face constant threats from viral infections which have 
the potential to affect mankind adversely, as we have experienced 
before. It would therefore be prudent to be at the forefront in 
tackling these threats. 
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INTRODUCTION
The mere mention of virus infection is typically  bad news for 
patients. Viral infections can vary from a mild infection to fatal ones. 
Fortunately, the vast majority of viral infections are asymptomatic. 
Most viral infections are self-limiting which means that the patients 
will recover regardless of whether they are treated. Humans and in 
fact all living things have been constantly interacting with viruses. 
Whether or not the humans will end up with an infection will 
depend on the ability of their immune systems to counteract the 
invasion of viruses. 
 It has been proven throughout human history that before the 
advent of vaccines viruses posed a serious threat to mankind. It 
had the potential to wipe out the human population. The influenza 
epidemics and pandemics are good examples. Epidemics (or 
outbreaks) occur on a regular basis, especially that caused by highly 
contagious viruses, such as respiratory viruses and the measles 
virus. Measles epidemics, for example, are still a serious threat in 
Africa, even though an excellent vaccine is available. This shows 
that the threat from viruses is still relevant and remains dangerous 
to mankind.
 Pandemics occur when an epidemic reaches beyond a few 
continents by which time a large population of the world would 
be at risk, predominantly facilitated by the ease of modern day 
travel. An excellent example is where in 2009 the H1N1 pandemic 
influenza A reached the entire world within a span of a few months. 
It has now evolved to become part of the seasonal human influenza. 
Though the pandemic was for the most part brought under control, 
it is still prevalent in parts of India, making us aware that it is not 
easy to contain a virus when its transmission involves a respiratory 
route. 
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 In Malaysia, we have our fair share of viral infection threats, 
namely, dengue, Nipah virus encephalitis and enterovirus 71 
infections. Additionally there is also the serious threat of blood-
borne infections such as the human immunodeficiency virus 
(HIV), hepatitis B and hepatitis C. The issue of increase in vaccine-
preventable diseases (VPD) is of particular importance in the wake 
of anti-vaccine lobby groups’ claims that current vaccines are 
harmful to children. Dengue epidemics can also be considered to be 
beyond control as we are dealing with an aggressive and ‘perfect’ 
mosquito, Aedes sp, where its eggs are able to survive harsh weather, 
and are pre-loaded with viruses. The mosquito typically takes 
multiple small bites to achieve a full meal (interrupted meals) and 
thus is able to transfer the virus to multiple people per full meal. 
 One of the first major fatal virus outbreaks that occurred in 
Malaysia was the Nipah virus outbreak. It lasted for nine months 
beginning from late 1998 and resulted in 265 cases of acute 
encephalitis with 105 deaths. Humans contracted the infections 
through close contact with infected pigs. The pigs acquired the 
Nipah virus from a natural reservoir host, the flying foxes, Pteropus 
hypomelanus and Pteropus vampyrus (Looi & Chua, 2007). The 
outbreak was halted after the culling of over one million pigs which 
almost caused the billion-dollar pig farming industry to collapse. 
 Malaysia is currently vigilant of epidemics happening 
elsewhere, as in the case of the Ebola virus and Zika virus. Contact 
surveillance is definitely necessary whenever an imported case is 
reported in Malaysia. The threats of coronaviruses, especially the 
SARS coronavirus and MERS coronavirus, are even more serious 
and the impacts are even greater if the infections spread among 
the population in Malaysia. The threats of the spread of deadly 
infectious diseases are real and we must thus be  ready to deal with 
them. 
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 Viruses are nanosized ‘microorganisms’ that are found in 
abundance on this planet, together with other microorganisms such 
as bacteria and fungus. Unlike bacteria or fungi, viruses are too 
tiny to have their own replication mechanism and therefore, utilise 
the hosts’ cell proteins and enzymes for replication. This means 
that they have to depend on getting entry into cells and ‘hijack’ the 
cellular mechanisms in order to survive. In doing so, the host cells 
are forced to replicate and generate millions of the virus progeny. 
This may have an impact on the cells themselves. Some cells will 
be damaged, either mildly or severely, while some would not be 
damaged. The destruction of the cells will eventually manifest as 
clinical disease. 
 Our immune system plays an important role in preventing these 
viruses from invading more cells. The lymphocytes play a central 
role in such control. There is thus a complex interplay between the 
virus and our immune system which will determine the outcome 
and severity of the infection. 
 If there is no prior exposure to the virus, the infection can be 
severe, especially if the virus is one known to cause significant 
cellular destruction. A good example is the Ebola virus, where it 
affects the endothelial cells and causes severe haemorrhage, which 
is the effect of the Ebola viral disease. This also applies to HIV 
where the virus slowly destroys human lymphocytes rendering them 
helpless against infections from other microorganisms, even though 
such infections would be ‘trivial’ infections in a healthy human. On 
the other hand, an ‘over-reacting’ immune system will also create 
problems for humans and manifest as a clinical disease. 
 In infections due to the severe acute respiratory syndrome 
(SARS), patients die due to massive release of cytokines (known as 
a cytokine storm) involving interferon gamma (Huang et al, 2005). 
This storm destroys the alveoli and makes breathing difficult for 
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the patients. A similar situation occurred in 2009, during the swine 
influenza epidemic, where the infection was found to be more deadly 
among the young than it was among the elderly.
 Apart from infections, it is now proven that viruses can cause 
cancer. Since the virus enter cells for replication, some viruses are 
able to manipulate the host cells’ genes, particularly, the tumour 
suppressor genes. The tumour suppressor gene is a gene that 
protects a cell from transforming into a cancer cell. The viruses can 
also induce mutation of these genes causing a loss or reduction in 
function, making it progress to cancer, usually in combination with 
other genetic changes. This leads to uncontrolled growth of the cells 
which eventually become cancerous. Another mechanism is direct 
destruction of the cells, as in the case of hepatitis B and hepatitis 
C. Due to constant destruction and repair, the liver, which has the 
ability to regenerate naturally, will present with hepatocellular 
cancer after 10 to 20 years.
 Virus survival and ability to sustain infectivity in hosts are 
attributed to its ability to mutate or modify genes. The mutations 
are outcomes of replication in the hosts where inefficiency in 
proofreading the genetic copies result in more mutations. Thus, 
DNA viruses, which have gene-proofreading mechanisms, have a 
slower mutation rate compared to RNA viruses. The advantage of 
mutation is that the virus is able to evade the immune responses 
of the host resulting from prior exposure, by changing protein 
configurations for attachment to the host receptors (also called 
antigenic determinants). Thus, humans can be infected several times 
by the same virus, which has mutated. 
 Viruses are thus, amazing creations and have the potential to 
create havoc among mankind and great potential to wipe out the 
entire human species.
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 As a clinical virologist and an academic, I play the role of 
educating both future doctors and future specialists in the country 
to be competent in recognising viral infections and in knowing 
what to do to control, overcome or prevent infections. In UPM 
we have established, recognised and accredited undergraduate and 
postgraduate programmes to accomplish this objective. The vital 
activity is research, which leads to discovery of new and relevant 
knowledge and consequently better strategies in our fight against 
infectious diseases in general, and specifically, viral infections.
 In this book, I will highlight my research involving four 
important issues: molecular epidemiology of respiratory viruses, 
prevention of hand-foot-and-mouth disease, beyond childhood 
hepatitis B immunisation and adult immunisation. These studies 
have contributed to new knowledge pertaining to the local context. 
Some of these studies were fundamental and can be used as a 
foundation for future studies. 
RESPIRATORY VIRUSES
Respiratory infection is one of the most common infections in 
humans where the majority are caused by viruses. In fact, there 
are more than 200 viruses that cause respiratory infections. Unlike 
bacteria, which can be treated with antibiotics, the treatment of 
respiratory infections is largely symptomatic (except for influenza 
and respiratory syncytial virus infections). This means that we are 
totally dependent on our immune system to counteract and prevent 
the infections. 
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LOCAL EPIDEMIOLOGY OF RESPIRATORY 
INFECTIONS
The epidemiology of respiratory viral infections is fairly well 
established worldwide. However, in Malaysia, related data is 
scant. Our first study on respiratory viruses was done in year 
1999, where we attempted to determine the epidemiology of 
respiratory viruses among paediatric patients hospitalised with 
respiratory infections, especially pneumonia, bronchiolitis and 
laryngotracheobronchitis, through techniques normally available at 
reference laboratories (Zamberi et al, 2003). The viruses implicated 
were the respiratory syncytial virus (RSV), adenovirus, influenza 
viruses and parainfluenza viruses. The methods used were direct 
antigen detection method, shell vial culture and the conventional 
culture method. The study spanned one year and a total of 222 
specimens were received. It showed a dual peak pattern, in the 
months of April and December. The mean age of the patients was 
13 months. Pneumonia (77.9%) was the most common clinical 
diagnosis followed by bronchiolitis (19.4%) and croup (2.7%). 
Viral aetiologies were confirmed in 23.4% of the patients. The 
most common respiratory virus isolated or detected was the RSV, 
followed by parainfluenza viruses, influenza viruses and adenovirus 
(Figure 1). This study provided an insight on the common viruses 
that caused serious respiratory infections that led to hospitalisation 
among paediatric patients in Malaysia. The epidemiology was 
almost similar to that in other studies carried out in other countries, 
where RSV was the predominant pathogen. Doctors should thus 
be vigilant especially when managing high risk patients, such as 
children with congenital heart disease, underlying respiratory 
conditions and premature babies.
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Figure 1  Distribution of respiratory viruses
GENETIC DIVERSITY OF RSV STRAINS
The respiratory syncytial virus (RSV) is a common virus that causes 
respiratory tract infections. It is a major cause of lower respiratory 
tract infections, namely bronchiolitis and pneumonia, in children. 
RSV can cause serious respiratory infections in high-risk paediatric 
patients, especially those with congenital respiratory or cardiac 
diseases, and also premature infants.
 The RSV genome consists of approximately 15,200 nucleotides, 
which are transcribed into 10 transcripts encoding 11 different 
proteins, nine structural and two non-structural proteins. Among 
these the G protein involves the attachment of the virus to the cell 
while the F protein assists in viral penetration, fusion and syncytium 
formation. 
 RSV is divided into two antigenic subgroups, A and B, on the 
basis of their reactivity with monoclonal antibodies against G and 
F proteins. Subtype A tends to cause more severe clinical illness 
and predominates in most outbreaks. Subtype B is known for its 
asymptomatic infections and infects a majority of the population. 
Despite its pathogenic importance there is currently no effective 
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anti-viral agent or vaccine for RSV. Thus far Ribavirin has been 
used to treat serious cases but the outcomes have been variable. 
 Ten years after our previous study, in 2009, we studied the 
genetic diversity of RSV strains among children below five years 
of age hospitalised with acute lower respiratory tract infections 
(ALRTI) at Hospital Serdang (Etemadi et al, 2013a). A total of 165 
nasopharyngeal aspirate (NPA) samples were obtained and tested for 
the presence of RSV and other respiratory viruses. RSV was found 
to be positive in 83 (50%) of the samples, using reverse transcription 
polymerase chain reaction (RT-PCR). Further classification of 
67 RSV strains showed that co-circulation of subgroups A and 
B, comprised 11/67 (16.4%) and 56/67 (83.6%) of the strains, 
respectively. There appeared to be a predominance of subgroup B. 
Further, phylogenetic analysis of 32 sequenced samples showed that 
all 9 RSV-A strains were clustered within the NA1 genotype while 
the remaining 23 strains of the RSV-B subgroup could be grouped 
into a clade consisting of strains with 60-nucleotide duplication 
region. They were further classified into newly discovered BA10 
and BA9 genotypes (Figures 2 and 3). The finding suggested the 
emergence of RSV genotypes of NA1 and BA. This study further 
supported the view of there being widespread dissemination of the 
BA genotypes in the community.
 This was the first documentation of the phylogenetic relationship 
and genetic diversity of RSV strains among hospitalised children 
diagnosed with ALRTI in a local hospital. Understanding the 
epidemiology and evolution of the strains will help in designing 
effective vaccines in future.
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Figure 2  Phylogenetic tree for RSV group A nucleotide sequences 
based on the second variable region of the G protein (270 bp) 
constructed by the Bayesian analysis method using MrBayes 3.0 
software.
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Figure 3  Phylogenetic tree for RSV group B nucleotide sequences 
based on the second variable region of the G protein (270 and 330 
bp) constructed by the Bayesian analysis method using MrBayes 3.0 
software.
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THE SEARCH FOR AN ANTI-RSV AGENT
The current treatment of RSV is very selective on severe cases, as 
in the case of severe RSV-induced bronchiolitis. A broad-spectrum 
antiviral agent known as ribavirin has been used for many years 
to treat such infections. It is a nucleoside analogue agent, which 
interferes with RNA metabolism required for viral replication. It is 
mainly administered in aerosolised form but oral and intravenous 
formulations have also been used. The problem however is that 
the outcomes have not been consistent and there are also concerns 
over toxicity for this age group, especially in terms of respiratory 
deterioration. Ribavirin is teratogenic and hence, should be avoided 
for female staff. The oral and intravenous formulations are also 
associated with haematological toxicity and are contraindicated in 
renal impairment (Brendish & Clark, 2017). 
 The search for effective anti-viral agents against RSV is 
currently on going. Many potential candidates have undergone 
various phases of clinical trials but unfortunately, to date, there is 
still no concrete positive outcome. 
 Our research team thus embarked on an innovative method to 
target the respiratory syncytial virus. The method involved the use 
of small interfering RNA or siRNA. It is a class of double-stranded 
RNA molecules, usually 20 to 25 base pairs in length and operating 
within the RNA interference (RNAi) pathway. It prevents translation 
of genes by interfering with the expression of specific genes with 
complementary nucleotide sequences. This process will degrade 
the mRNA after transcription. In principle, siRNA can knock down 
any gene and hence, this powerful characteristic can be used to 
inactivate viruses.
 Apart from the G and F proteins, RSV has other proteins which 
are involved in the replication process. The small hydrophobic (SH), 
matrix (M) and M2 proteins are virus transcription factors while 
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the nucleoprotein (N), phosphoprotein (P) and the large (L) protein 
are RNA dependent RNA polymerase present in the nucleocapsid 
of the virus. 
 The M2-2 protein of respiratory syncytial virus is particularly 
important in the regulation of viral RNA transcription and 
replication. It provides an initial high level of mRNA leading to 
RNA synthesis in the form of a regulatory ‘switch’ to facilitate 
virion assembly. This switching is then followed by a shift in favour 
of genomic viral RNA assembly and the lack of this M2-2 gene can 
effectively attenuate virus growth.
 The M2-2 protein could be a potential anti-viral candidate 
against RSV infection. In our study, we designed and validated 
siRNAs that specifically target the RSV M2-2 gene (Chin et al, 
2016). Four siRNAs targeting different regions of the M2-2 gene 
were designed using a web tool. In-vitro evaluation of the siRNAs 
silencing effect was performed by using an RSV-infected Vero 
cell line. Viral M2-2-linked GFP recombinant plasmid was co-
transfected with non-targeted siRNA, pooled siRNA, siRNA 1, 
siRNA 2, siRNA 3 and siRNA 4 using synthetic cationic polymer. 
The silencing effect on the M2-2 gene at the protein level was 
measured both qualitatively and quantitatively using fluorescence 
microscopy and flow cytometry. 
 The inhibition of the RSV M2-2 gene was further investigated 
at the mRNA level by transfecting siRNAs with viable RSV. The 
effectiveness of siRNA in silencing the gene at the mRNA level 
was assessed using quantitative real time PCR. 
 This study showed that all the four siRNAs designed could 
effectively and efficiently silence the M2-2 gene. siRNA 2 showed 
the highest (98%) silencing effect at the protein level and siRNA 
4 with 83.1% at the mRNA level (Figure 4) 
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Figure 4  Fluorescence microscopy view of co-transfection of viral 
M2-2 linked GFP recombinant plasmid with 5 different siRNAs 
(siRNA1, siRNA2, siRNA3, siRNA4 and pooled siRNA) at 50 nM. 
Low intensity of green fluorescence emission when compared to the 
control indicates that viral M2-2 linked GFP recombinant plasmid 
strongly reduced GFP expression and vice versa. Scramble siRNA 
served as a negative control. Observation was made 48 h post infection. 
Scale bars indicate 10 µm. 
Viral assay was performed to validate this finding. It showed no 
cytopathic effects 6 days post-infection with the siRNAs being 
compared to the control. These experiments confirmed that the M2-2 
gene can be successfully silenced by siRNA, leading to successful 
inhibition of RNA replication and transcription.
 In conclusion, this study showed the effectiveness of siRNA in 
silencing the M2-2 gene both at the protein and mRNA levels, and 
thus it could potentially be used as a novel therapeutic agent in the 
treatment of RSV infections. However, further study is warranted 
to investigate the  M2-2 protein silencing effect and subsequent 
inhibition of RSV infection. 
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THE IMPACT OF THE HUMAN RHINOVIRUS ON 
RESPIRATORY INFECTIONS
Human rhinovirus (HRV) is one of the most common viruses that 
infect man. It belongs to the Picornaviridae family of viruses and 
comprises three species,      HRV-A, HRV-B and HRV-C. In terms of 
size, it is also one of the smallest viruses, about 30 nm in diameter. It 
predominantly causes the common cold and other upper respiratory 
tract infections, such as sinusitis and otitis media. The environment 
in the nose, with temperature lower than that of body temperature, 
between 33 to 35oC, facilitates its growth. There are currently 160 
serotypes of this virus which pose a challenge in terms of vaccine 
development. 
 Human rhinoviruses spread through aerosols of respiratory 
droplets and contaminated surfaces (or fomites). HRV infection 
has  traditionally been associated with upper respiratory infections. 
When common cold infections occur, typical symptoms such as sore 
throat, runny nose, nasal congestion, sneezing and cough will appear. 
While these symptoms appear to be mild, there are accumulating 
evidences that HRV has increasingly become an important pathogen 
in causing ALRTI. In relation to this there are reported cases of 
bronchiolitis and pneumonia among young children, exacerbations 
of asthma in older children and exacerbations of chronic obstructive 
pulmonary disease and pneumonia in older age groups (Etemadi et 
al 2017). 
 We thus went on to investigate the role of the human rhinoviruses 
in causing ALRTI in the local context. 
 We investigated the molecular epidemiology, demographic and 
clinical characteristics of HRV among children hospitalised with 
ALRTI in Hospital Serdang (Etemadi et al, 2013b). Nasopharyngeal 
aspirates were collected from 165 children of less than five years of 
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age. The samples were subjected to reverse transcriptase-PCR for 
HRV. Phylogenetic analysis of the VP4/VP2 and 5’-NCR regions 
was used to further characterise the HRV. Other respiratory viruses 
such as RSV and influenza A virus (IFV-A) were also investigated 
using semi-nested multiplex RT-PCR assay. Clinical parameters 
were analysed to differentiate between HRV, RSV and influenza A 
virus (IFV-A) mono-infections and between HRV species.
 We found that RSV (49/165, 29.7%) was still the most common 
cause of ALRTI in these patients. This is followed by HRV (36/165, 
21.8%) and IFV-A (10/165, 6.1%). It was noted that there were 18 
cases of co-infections especially with HRV, 14 were dual infections 
and four were triple infections (Table 1). The most prevalent 
multiple infection was HRV-RSV co-infection (11/18, 61%). 
Table 1 HRV co-infections with other respiratory viruses
 Altogether, 54 of the 165 (32.7%) samples were positive for 
HRV. Majority of the HRV serotypes (61.1%) were identified as 
HRV-A. No HRV-B was detected. We were the first group to detect 
the newly discovered HRV-C in Malaysian patients. 
 The mean age of the HRV-infected patients was 11.8 months as 
compared to RSV (9 months) and IFV-A (12.7 months). Interspecies 
comparison revealed that the mean age of HRV-C-infected patients 
was significantly higher than the HRV-A-infected ones (16.3 vs 7.1 
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months, p=0.047). The majority of the HRV-A infections were found 
in children of 6 to 11 months of age, while  HRV-C infections were 
among those of 12 to 23 months of age.
 The clinical features of the children infected with the three 
common viruses (HRV, RSV and IFV-A) were compared. Children 
infected with HRV were admitted significantly earlier than 
those infected with RSV and IFV-A. In terms of the duration of 
hospitalisation, children infected with HRV had the shortest duration 
(1.9 days, p<0.001) compared to those infected with RSV (4.0 days) 
and IFV-A (4.8 days). There were however, no distinctive differences 
between the three infections. It was noted that the occurrence 
of fever with HRV infections was less than that in the RSV and 
IFV-A infections. Disease severity characterised by the need of 
oxygen, admission to intensive care unit and prolonged hospital 
stay however did not differ among the different viral infections. 
It was reported that diarrhoea was significantly higher in the IFV-
A-infected patients (40%, p=0.031) than in the HRV- (8.3%) and 
RSV-infected (14.3%) ones. 
 In HRV-infected patients, pneumonia was the most common 
discharge diagnosis followed by bronchiolitis and post-viral wheeze. 
In comparing HRV-A and HRV-C infections, vomiting occurred 
almost two times more with HRV-C infections. However, the HRV-C 
patients were more likely to present rhonchi and post-viral wheeze 
than the HRV-A patients. There was no difference in disease severity.
 Phylogenetic analysis of HRV strains revealed a very large 
variation in concomitantly circulating strains (Figure 5 and Figure 
6) and was related to other strains from other geographical areas. 
This indicated that repeated HRV infection by various strains is a 
norm, as these strains do not confer cross-immunity against one 
another. 
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Figure 5  Neighbor-joining dendrograms depicting phylogenetic 
relationships of human rhinovirus species A strains in the 
420-nucleotide region in VP4/VP2. Red type indicate strains of this 
study while reference sequences are shown in black. Branches showing 
>70% bootstrap support are indicated. 
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Figure 6  Neighbor-joining dendrograms depicting phylogenetic 
relationships of human rhinovirus species C strains in the 
420-nucleotide region in VP4/VP2. Red type indicate strains of this 
study while reference sequences are shown in unbold type. Branches 
showing >70% bootstrap support are indicated. 
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 This study highlighted a couple of important points. Firstly, it 
emphasised the fact that HRV can cause ALRTI, and therefore, it is 
important to seriously consider this virus as an important cause of 
children being hospitalised with respiratory infections. The HRV-A 
strain seemed to be the most prevalent. The absence of HRV-B 
indicates that it plays a minor role in disease severity. Further, the 
detection of the newly discovered HRV-C revealed that it has the 
potential to pose a major respiratory disease burden. This study 
also revealed some differences in terms of clinical features between 
HRV-A and HRV-C. Secondly, the study revealed that the use of 
molecular-based techniques such as polymerase chain reaction 
(PCR) increased the chances of virus detection, which will give 
more value in the clinical management of these patients.
 We went on further to investigate the host-virus responses 
in HRV infections (Etemadi et al, 2017). We wanted to find out 
the molecular mechanisms of the host’s response towards HRV 
infection. This can serve as a platform to develop effective anti-
HRV therapeutic strategies. We chose HRV-B as virus model and 
A549 cells (human adenocarcinoma alveolar basal epithelial cells) 
as the host model. The virus and the cells were maintained and 
standardised in terms of quantity. After determining the appropriate 
multiplicity of infection (MOI), the A549 cells were infected with 
HRV-B. 
 HRV-B induced specific cytopathic effects (CPE),  characterised 
by shrinkage and rounding-off as well as detachment and destruction 
of cell layers, as observed by light microscopy (Figure 7). CPE 
started to appear at 12 hours post-infection (hpi) on A549 cells and 
continued to increase up to 48 hpi. Analysis of the virus propagation 
in cell culture supernatant confirmed the time-dependent increase 
of viral RNA up to 48 hpi.  
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Figure 7  Infection of A549 cells with HRV72. Representative 
microphotographs of A549 cells either mock-infected (upper) or 
infected with HRV72 (below) at various time points. The cells were 
visualised using a phase contrast microscope at 200x magnification. 
 RNA was extracted from the cells using standard techniques. 
After ensuring that there was appropriate RNA amounts as indicated 
by RNA Integrity Number, microarray hybridisation was performed 
using Affymetrix Genechip technology, covering more than 20,000 
genes. Representative of differentially expressed genes from 
different functional groups including chemokines (CXCL8, CCL20, 
CXCL3), anti-apoptotics (BCL2A1), transcription factors (FOSL1, 
JUN, and EGR1) and signal transduction mediators (DUSP6 and 
GNB4) were selected and validated by qRT-PCR. The expression 
profiles of the IFN genes including IFN-β, Il29 (IFN-λ1) and IL28 
(IFN-λ2/λ3) were also further evaluated using qRT-PCR. 
 It was found that HRV infection modified a large number of 
genes in a timely manner. The transcriptional response to HRV 
infection was characterised by significant up- and down-regulation of 
the genes. A comparative analysis of three independent experiments 
between HRV-infected and mock-infected cells identif ied 
collectively 991 differentially expressed (DE) genes across all time 
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points, from which 459 (46%) were up-regulated and 532 (54%) 
were down-regulated. It appeared  that the down-regulated genes 
surpassed the up-regulated genes. DE genes at 6 hpi (187 genes 
up-regulated vs. 156 down-regulated) were significantly represented 
by gene ontologies related to the chemokines and inflammatory 
molecules exhibiting the characteristics of viral infection. The 75 
up-regulated genes surpassed the down-regulated genes (35) at 
12 hpi and their enriched ontologies fell into discrete functional 
entities, such as regulation of apoptosis, anti-apoptosis and wound 
healing. At later time points of 24 and 48 hpi, predominated down-
regulated genes were enriched for extracellular matrix proteins and 
airway remodeling events (Figure 8). The overlaps of the DE genes 
across all-time points are displayed using Venn diagrams in Figure 
9.
Figure 8  Summary of DE genes induced by HRV72. The DE genes 
were determined at four time points by filtering of the genes at p-value 
0.05 and with a fold change of 1.5. 
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Figure 9 Venn diagram showing overlap of DE genes in HRV-infected 
cells compared with mock-infected A459 cells with 1.5-fold (p-value 
0.05). 
From analysis of the cellular gene expression of HRV infection 
based on four time points using an in vitro system, this study 
revealed the comprehensive gene expression profile of epithelial 
cells’ response to HRV infection. This study thus aids the foundation 
for further investigations on the genes and their pathways that might 
be involved in the pathogenesis of the HRV infection. Ultimately, 
this fundamental knowledge can lead to the development of possible 
targets for treatment and even prevention. 
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FIRST MALAYSIAN REPORT OF BOCAVIRUS 
INFECTION
In 2012, our group became the first in Malaysia to report the 
presence of human bocavirus in Malaysian patients (Etemadi et 
al, 2012). It was originally reported by Allander and co-workers 
in 2005, in respiratory secretions from children with respiratory 
infections in Sweden (Allander et al 2005). 
 Human bocavirus (HBoV) is classified under a family of small 
viruses called Parvoviridae. Human bocavirus is a non-enveloped 
and icosahedral virus. It is very tiny, with a diameter of 18 to 26 nm 
and a genome size of 5.3 kb. Since its discovery, it has been reported 
worldwide in young children with respiratory or gastrointestinal 
symptoms. HBoV has four different genotypes, HBoV 1 to 4. 
 The patient in whom the virus was discovered was a 13-month-
old baby with a history of asthma who had been admitted to Hospital 
Serdang. He was admitted due to wheezing after experiencing 
fever and cough for a few days. Physical examinations revealed 
a tachypnoeic child with bilateral coarse crepitations. His 
nasopharyngeal aspirate (NPA) was sent for testing. No bacterial 
infection was detected and direct immunofluorescence assay was 
negative for influenza A virus, influenza B virus, parainfluenza 
types 1, 2 and 3, adenovirus and respiratory syncytial virus. We 
then carried out our own in-house molecular testing, utilising both 
multiplex and regular PCR methods, for several other viruses. 
They were negative for human metapneumovirus, coronaviruses 
OC43, 229E, HKU11 and NL63 and rhinovirus. Eventually, it 
tested positive for human bocavirus, which was confirmed by PCR 
(Figure 10).
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Figure 10 Agarose gel electrophoresis of human bocavirus PCR 
product.  
Line M: Marker,  
Line 1: using confirmation primer set (420 bp)  
Line 2: using screening primer set (354 bp)
 This study emphasises the fact that newly emerging viruses can 
cause substantial infections in a susceptible population. Advanced 
diagnostic techniques are thus needed to detect such viruses. The 
addition of such techniques in routine diagnostic laboratories 
can assist doctors in making informed decisions in the clinical 
management of their patients.
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FIRST MALAYSIAN REPORT OF HKU1 
CORONAVIRUS INFECTION 
Coronavirus is an enveloped RNA virus with a genome size of 
approximately 26 to 32 kb, the largest for an RNA virus. It primarily 
infects the upper respiratory and gastrointestinal tract of mammals 
and birds. There are currently six strains of coronaviruses that infect 
humans: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, 
SARS-CoV and MERS-CoV. Human coronaviruses predominantly 
cause the common cold, second to rhinovirus infections. It can also 
cause pneumonia and severe pneumonia, especially the SARS-CoV 
and MERS-CoV.
 Human coronavirus HKU1 was first discovered in 2005 in 
Hong Kong and had never been reported in our country. In 2012, 
we reported the first Malaysian case of HCoV-HKU1 infection 
(Amini et al 2012). It was a case of acute pharyngitis in a 3-year-old 
patient where the patient’s asthma was exacerbated. She presented 
acute respiratory symptoms and asthma wheeze. NPA was collected 
and sent to our laboratory for analysis. Bacterial infections were 
excluded through the tests performed. Molecular methods, using 
a highly sensitive commercial multiplex (Seegene, Korea), were 
then employed for the detection of 15 respiratory viruses, which 
include influenza A and B viruses, human respiratory syncytial 
virus A and B, parainfluenza 1, 2, 3 and 4 viruses, human bocavirus, 
human metapneumovirus, adenovirus, rhinovirus, enterovirus and 
coronaviruses OC43/HKU1 and NL-63/229E. It yielded positive 
results for coronavirus OC43/HKU1. To differentiate between 
the two coronaviruses, we designed our own in-house PCR test 
which was positive for the HKU1 virus, confirmed by nucleotide 
sequencing (Figure 11).
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Figure 11  Ethidium bromide staining of 2% agarose gel showing RT-
PCR product (443 bp) of human coronavirus HKU1–specific primers. 
Lane M, size marker (100 bp); Lane 1, Negative control RT- PCR mix; 
Lane 2, HKU1; Lane 3, OC43.
 This study emphasises the need to be vigilant in considering 
emerging viruses when diagnosing patients in Malaysia.
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HAND, FOOT AND MOUTH DISEASE
Hand, foot and mouth disease (HFMD) is one of infections that 
affect children. The common causative agents are predominantly 
enterovirus 71 (EV71) and Coxsackievirus A16 (CA16). Other 
enteroviruses such as CA6 and echovirus can also cause the disease. 
 Enterovirus 71 and Coxsackievirus A16 are RNA viruses from 
the same genus, Enterovirus in the Picornaviridae family. They 
are predominantly spread through the faecal-oral route and also 
through contact with an infected person’s saliva, faeces, respiratory 
aerosols or contaminated water. They can remain in faecal matter 
for up to 11 weeks. Colonisation occurs in the intestinal tract and 
then spreads into the bloodstream and eventually to the organs. 
 HFMD patients are commonly children and typically present 
symptoms of fever, mouth ulcers (also known as herpangina) and 
vesicles on the palms and soles. It is usually mild in nature. Further, 
in children less than two years of age, atypical rashes are frequently 
seen. In adults the viruses can cause upper respiratory tract 
infections. Although HFMD is a self-limiting disease, the EV71 
can cause severe and potentially fatal neurological diseases such 
as encephalitis (usually in the brainstem), acute flaccid paralysis 
and meningitis. These symptoms can develop in a matter of hours 
or days. CA16, on the other hand, is associated with mild HFMD.
 In the 1990s, epidemics of EV71 infections were observed 
in Europe and eventually spread to Asia. In 1997, Malaysia was 
also affected where outbreaks started in Sarawak and then spread 
to Peninsular Malaysia, with reports of fatalities among children 
(AbuBakar et al, 1999). A total of 35 children died in the outbreaks. 
CA16 as the cause of HFMD has also been reported in Malaysia 
since 2000 (Podin et al, 2006). It was seen during the outbreak or 
inter-outbreak of EV71. Outbreaks of CA6 have also been reported 
in many other countries, such as Singapore, Taiwan and Japan.
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 We embarked on a small-scale study to look at the epidemiology 
of HFMD among children below twelve years of age in Seri 
Kembangan, Selangor (Beh et al, 2014) during a non-outbreak 
period. A total of six general practitioner clinics were involved in 
the study. The specimens collected were throat swab, vesicles swabs 
and rectum swabs. The specimens were subjected to semi-nested 
reverse-transcription polymerase chain reaction (snRT-PCR) and 
positive specimens were sent for sequence analysis. Phylogenetic 
analysis was then carried out.
 A total of 28 cases of HFMD were detected and only twelve 
(42.9%) tested positive for viruses by snRT-PCR. There was no 
significant gender or age difference among those infected. The 
mean age of the patients with positive results was 3.6 years old. 
The breakdown of causative viruses identified were seven (58.3%) 
CA6, two (16.7%) CA16 and three (25%) EV71. Phylogenetic trees 
of the three viruses were then constructed based on the partial VP1 
sequences. 
 The CA6 strains were shown to be closely related to the Taiwan 
and Japan strains (Figure 12). Further, the CA16 were identified 
as being from genotypes B2b and B2c. The subgenotype B2b 
was closely related to China strains isolated in 2011. However, 
subgenotype B2c was similar to Malaysian strains isolated in 2007. 
During the period 1997 to 2003, subgenotype B2a was dominant 
while after 2005, subgenotype B2c was also detected (Chan et al, 
2012). Other subgenotypes such as subgenotype B1 had also been 
reported in Sarawak, from 1998 and 2000.
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Figure 12  Phylogenetic tree of CVA6 VP1 was constructed using 
partial VP1 sequences (nt 2627-3357) of the detected isolates. CVA6 
strains from other countries were included to show the relationships 
between the detected CVA6 strains. The dots indicate CVA6 strains.
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 The EV71 strains detected in this study were from genotype 
B5 and closely related to isolates from Selangor and Johore. This 
has been the dominant subtype circulating in Malaysia (Chan et al, 
2012). 
 This small study illustrated the importance of molecular 
epidemiology in HFMD surveillance, as it will enhance intervention 
in the event of outbreaks and also fatal cases. Clinical diagnosis 
alone is not adequate and the simple serological tests are not reliable 
and accurate. On the other hand, molecular epidemiology will 
provide an accurate picture of the prevailing viruses in circulation 
and the public health authorities can then be vigilant in monitoring 
related cases and prevent outbreaks.
THE DEVELOPMENT OF THE ENTEROVIRUS 71 
VACCINE
Looking at the potential threat of EV71 and in the absence of an 
effective treatment, it is worthwhile to develop a vaccine which can 
potentially protect millions of life globally. Over the years there 
have been several types of EV71 vaccine candidates, including 
attenuated strains, inactivated whole-virus, virus-like particles 
(VLP), recombinant proteins, recombinant vectors and peptide 
vaccines (Yi et al, 2017). 
 Thus far, the inactivated whole virus technology seems to be 
the most effective strategy in producing the vaccine. There are 
currently two approved inactivated whole virus vaccines available 
for commercial use in China. Immunisation with the formalin 
inactivated EV71 strain can elicit high levels of virus-specific 
antibodies and  the important characteristic of cross-neutralisation 
activity. Further, clinical trial results have indicated that is results in 
90% prevention against EV71-associated HFMD or herpangina and 
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80% of other EV71-associated disease symptoms. However, these 
approved vaccines are specific for EV71 and do not protect against 
other HFMD-causing viruses, such as CA16. It is thus worthwhile 
to note that a bivalent formalin-inactivated EV71/CA16 vaccine is 
currently under development (Yi et al, 2017). 
 Immunisation with recombinant VP1 protein of EV71, 
expressed in Escherichia coli, yeast or the baculovirus system, can 
induce high levels of EV71 VP1-specific IgG antibodies but the 
titre produced is still lower than that of the inactivated whole virus. 
Other technologies such as virus-like particles, DNA vaccines and 
recombinant vector vaccines are currently still under development. 
 Many years ago, I was involved in the development of a vaccine 
against EV71 using DNA vaccine technology. The objectives of the 
study were to design and construct a DNA vaccine using the viral 
capsid protein (VP1) gene of EV71. This vaccine candidate was 
tested in vitro for the expression of the VP1 protein in a mammalian 
cell culture  followed by in vivo testing on its ability to express 
protein and to elicit immune responses in mice (Wong et al, 2007). 
 The VP1 genes of EV71 from two local outbreak isolates 
were amplified using PCR and then inserted into a eukaryotic 
expression vector, pVAX1. The 3.9 kb recombinant constructs were 
transformed into competent Escherichia coli cells and the positive 
clones were screened and selected using PCR analysis, restriction 
digestion analysis and DNA sequencing. The constructs were also 
tested for protein expression in Vero cells. The VP1 protein was 
successfully expressed in the mammalian cell line and detected 
using RT-PCR, Indirect Immunofluorescence Assay (IFA) and 
western blotting.
 In in vivo studies, female Balb/c mice were immunised with the 
DNA vaccine constructs through intramuscular injection. ELISA 
and virus neutralising assay were performed to detect the presence 
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of anti-VP1 IgG in the mice and its neutralising effects against 
EV71. 
 Following DNA immunisation, the antigenic viral antigens 
expressed from plasmids seemed to be expressed, folded and 
assembled in the same manner as when they are expressed during 
a natural viral infection. 
 The anti-VP1 IgG levels in the mice immunised with the DNA 
vaccine constructs increased after the first booster but declined 
following the second booster, probably due to a shift towards cellular 
immune response. The anti-VP1 IgG in these mice  exhibited 
neutralising activity against EV71. This study demonstrated 
promising results on the use of the vaccine against EV71. 
 The route of entry of the EV71 infection is through the oral 
route but the vast majority of vaccine administration is via the 
intramuscular route, which in this case is less ideal. While the 
intramuscular delivery system has been fairly well established, it 
still requires injection through a needle, which can be painful and 
may be subject to adverse events. In the case of EV71 infections, it 
does not mimic a natural route of infection. We thus embarked on 
developing a candidate EV71 vaccine using the oral route (Saeed et 
al, 2014a). An oral mucosal vaccine seems to be a good alternative 
because it provides a medium that is as close to natural infection 
as possible. The duration of exposure to the vaccine is also longer, 
triggering a longer interaction with the antigen presenting cells and 
the lymphocytes.   
 Despite the mentioned advantages, an oral vaccine is inherently 
problematic because the vaccine will be subjected to digestion in the 
gastrointestinal tract, particularly in the stomach, due to increased 
acidity and gastric digestive enzymes. Thus, this approach will 
render the vaccine less useful due to degradation. 
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Administrating the vaccine via the buccal route thus seems to be the 
more ideal choice. The exposure of the antigen to the surrounding 
immune cells will generate a different type of antibody, which is 
immunoglobulin A (IgA). IgA is a type of antibody that plays a 
crucial role in the immune function of the mucous membranes. 
Its dimeric form is the most prevalent and is called secretory IgA 
(sIgA). It is found in mucous secretions in the body, such as tears, 
saliva, sweat and secretions from various organs. The secretory 
component of sIgA protects the immunoglobulin from a harsh 
environment such as that in the gastrointestinal tract. 
 The challenge of this route of administration is to maintain 
the vaccine in the oropharyngeal area for as long as possible to 
ensure maximum interaction with the immune cells. This requires 
a carrier that is able to adhere to the mucosal surface and generate 
a sustained release of antigens. The carrier also needs to protect 
the peptides, protein, epitopes or antigen of interest against the 
adverse environment and to deliver them to the intended location 
without degradation or change in conformation. The choice of 
a good delivery system is thus very important, ideally a system 
that can offer controlled drug release (Shen et al, 2013). These 
include chitosan, alginate, starch, polyoethylene glycol and calcium 
carbonate. 
 Chitosan is safe and biodegradable (Saeed et al, 2015a). 
Its other favourable properties include thermostability, low 
swelling, extended release, highly adhesive and viscous, as well 
as providing smooth reversible encapsulation (Bowmab & Leong, 
2006). Chitosan could enhance mucosal delivery of drugs due to 
its muco-adhesiveness. It is no surprise that chitosan is also used 
in therapeutics, where it slows down the release of loaded drugs. 
Chitosan is expected to protect antigen epitopes in a controlled 
release manner. 
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 Alginate is another medium that is worthy of consideration. 
It is a naturally occurring polymer typically obtained from brown 
seaweed. It has numerous applications in biomedical science and 
engineering. Its favourable properties include biocompatibility, low 
toxicity, relatively low cost and ease of gelation. It can be made 
into hydrogels, which has wide applications including delivery of 
antigens as in the case of vaccine design. 
 In the choice between chitosan and alginate as the most 
suitable delivery system, this study looked at calcium phosphate 
released under artificial conditions mimicking gastric juices of 
pH 2 and body temperature of 37oC. The results showed chitosan 
to be superior to alginate in terms of size, formulation stability, 
swelling and crosslink reversibility. Hence, chitosan was chosen 
as the delivery system for this study (Saeed et al, 2014b).
 The next step was to select the most appropriate adjuvant. 
Adjuvants work by binding to vaccine epitope, peptide or antigen, 
increasing its molecular weight, delaying its clearance from the 
circulatory system by the phagocytic cells, improving its antigenic 
uptake by macrophages,  and extending its release to the immune 
cells. These characteristics lead to the control of adjuvant release, 
which could prolong antigen delivery, presentation and activation 
of a measurable number of lymphocyte clones. Ultimately, the main 
outcome is an elevated vaccine response and enhanced immune 
protection. 
 In this study, calcium phosphate was chosen as the adjuvant. 
It has long been used by researchers to promote both systemic and 
mucosal immunity and is a non-toxic, biodegradable and non-
antigenic adjuvant (Saeed et al, 2014a).
 One of the objectives of this study was to determine the 
appropriate size of the calcium phosphate, either nano or microsizes, 
and the appropriate concentration of chitosan. Both calcium 
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phosphate sizes were tested against a combination of several 
chitosan concentrations. The combinations were tested for safety 
and their ability to release calcium over a period of 96 hours.
 The delivery system was tested against human liver cells 
Hep-G2 to confirm its safety. The results showed that calcium 
phosphate of nanosizes could be released faster than that of 
microsizes. In terms of sustained release, chitosan of above 
1% concentration showed extended delivery of adjuvants. This 
information is very useful in designing vaccine delivery. In order 
to have a rapid but sustained delivery of the antigen of interest, the 
size is thus preferably nanosize and enveloped in a slightly higher 
concentration of chitosan.
 This study then proceeded to determine the best mode of 
vaccine administration (Saeed et al, 2015b). Inactivated EV71 were 
absorbed to nanosize and microsize calcium phosphate adjuvants. 
Both adjuvants were then administered through intradermal 
and intramuscular routes. The objective was to find the best 
antigen-chitosan-calcium phosphate size and administration route 
combinations. 
 This study resulted in two important findings. Firstly, the use 
of nanosize adjuvant in the vaccine delivered through intradermal 
administration (0.1 ml) induced the highest level of virus specific 
antibodies compared to that of the microsize adjuvant. This is an 
indicator of the importance of using nanosized antigen for increased 
release to the immune cells. Secondly, the use of intradermal 
administration requires one-tenth of the vaccine dose compared to 
intramuscular administration, to achieve the same level of antibodies 
production.
 The study went on to determine the best vaccine delivery 
strategy - buccal, intradermal or both routes. The results showed that 
combined vaccine delivery by both buccal and intradermal routes 
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elicited the best immune response with enhanced production of both 
IgG and IgA antibodies. This contributes to achieving both systemic 
and mucosal protection,  providing the ultimate protection against 
EV71 infections. Absorbing the inactivated EV71 into the nanosize 
adjuvant coated with chitosan deployed an improved immune 
response of specific IgA, even with a single buccal administration. 
 In conclusion, the development of an effective enterovirus 71 
vaccine still has a long way to go. Though at the moment we have 
two EV71 vaccines available (only in China), which comprise 
inactivated virus, its effectiveness is limited solely to EV71-related 
diseases. Our study attempted to develop a vaccine that is able to 
develop as close as possible to natural infection where the body can 
mount a good combination of antibodies production, particularly 
IgA, IgM and IgG. So far, a  strategy of combined buccal exposure 
and intradermal injections has shown good results.
BEYOND UNIVERSAL CHILDHOOD HEPATITIS B 
IMMUNISATION
Chronic hepatitis B is one of the most important causes of liver 
failure and liver cancer worldwide. It is caused by a DNA virus 
called the hepatitis B virus. It is a worldwide problem with more 
than 350 million chronic hepatitis B carriers. In Malaysia, there 
are an estimated 1.1 million chronic hepatitis B carriers as of 1998 
(Liaw et al, 2005). The estimated HBsAg prevalence in Malaysia 
in year 2000 was 0.77% (Ott et al, 2017).
 The hepatitis B virus is a member of the hepadnavirus family. 
The virus is 30 – 42 nm in diameter and consists of an outer lipid 
envelope enclosing the icosahedral nucleocapsid protein. The 
envelope contains proteins which are involved in viral binding to 
susceptible cells. The nucleocapsid covers the viral DNA and an 
enzyme called DNA polymerase. 
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 The virus produces in excess, surface antigens called HBsAg, 
which are composed of lipid and protein found on the surface of the 
virus. The presence of HBsAg is used as an indicator of infection. 
 Hepatitis B is transmitted through blood and body fluids. In high 
prevalence areas such as China and South East Asia the primary 
mode of transmission is through vertical (childbirth) and perinatal 
transmissions. However, in Africa, transmission is common among 
children, as in other moderate prevalence countries such as Eastern 
Europe and Japan. In low prevalence countries like the United States 
and Western Europe, hepatitis B is primarily transmitted through 
sex and injection drug use (Cluster et al, 2004). Other modes of 
transmission include surgical and dental procedures, tattooing or 
contact with objects contaminated with infected blood. 
 Hepatitis B may be either acute (and self-limiting) or chronic. 
In acute infections, the patients are able to clear the infection 
spontaneously over a span of weeks or months. The acute 
presentations are variable, from mild to severe. The patients  present 
symptoms of fever, nausea and vomiting, weakness and fatigue, loss 
of appetite, abdominal pain, dark urine, jaundice and joint pain. In 
general, children are less likely to be able to clear the viral infection 
compared to adults.
 More than 95% of infected adults and older children are able 
to recover and attain protective immunity for life. However, for 
younger children, only about 30% would be able to do so. The 
situation is worse for newborns who acquire the infection from 
their mothers, where 95% of the babies would not be able to clear 
the virus (Bell and Nguyen, 2009). More than 90% of children and 
less than 5% of adults present with chronic hepatitis B infections. 
Chronic hepatitis B infection is defined as the persistence of the 
“s” antigen for more than 6 months. 
Hepatitis B virus primarily interferes with the functions of the liver. 
It replicates in the hepatocytes. In the attempt to clear the virus, the 
host’s immune response causes damage to the liver cells, particularly 
by cytotoxic T lymphocytes. The persistent presence of this virus 
will result in attack of the liver cells (known as hepatocytes) 
causing consistent activity of necrosis and regeneration. This will 
result in scarring of the liver which will eventually transform into 
carcinogenesis leading to hepatocellular carcinoma. Depending 
on the host’s response to the virus, where some hosts are able to 
mount restricted immune response, the damage occurs persistently 
for a long time. 
 Hepatitis B accounts for 60% of liver cancer in Malaysia, 
especially among those of Malay and Chinese ethnicity, in addition 
to hepatitis C (11%), cryptogenic diseases (16%) and alcoholism 
(6%) (Goh et al, 2015). 
 In 1992, the World Health Organization recommended the 
integration of the hepatitis B vaccine into the national immunisation 
programmes of all highly endemic countries by 1995 and all 
other countries by 1997. Malaysia had already embarked on this 
programme since 1989. The programme consists of 3 doses, starting 
from birth, a second dose at 1 month of age and the third dose at 5 
months.
 Antibodies against hepatitis B surface antigen (anti-HBs) 
provide protection against hepatitis B infection, and thus, 
vaccination with HBsAg provides adequate immunity against 
hepatitis B. A minimum of 10 IU/L of anti-HBs should be mounted 
to attain a protective level against hepatitis B. 
 A summary of global immune response of more than 9,000 
infants from 20 countries revealed that a median of 98% infants 
achieved seroprotective anti-HBs after three or four doses of the 
hepatitis B vaccine (Shillie and Murphy, 2013). A slightly lower 
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median seroprotection rate of 93% was noted for infants weighing 
less than 2 kg. It is suggested that delaying the first dose of the 
vaccine until one month of life can increase the proportion of 
preterm infants attaining seroprotection. 
 In a community clinic in Malaysia, infant immune response 
to the vaccine was evaluated after completion of the primary 
immunisation series. A total of 572 infants were enrolled. About 
97% of the infants attained adequate anti-HBs levels of more than 
10 IU/L and no infant with HBsAg was detected among them, even 
among the infants born from mothers with chronic hepatitis B. This 
indicates that the 3-dose vaccine series is able to provide infants 
the necessary protection against hepatitis B (Cheang et al, 2013). 
 The implementation of the hepatitis B immunisation program 
has thus been a success (Ng et al, 2005). A cross-sectional 
seroprevalence study of hepatitis B in 190,077 schoolchildren in 
Malaysia, aged 7 – 12 years of age, showed a decline in HBsAg 
prevalence rates from 2.5% (1985) to 0.4% (1996). This suggests 
that the immunisation program has been the most effective measure 
in preventing vertical transmissions of the disease in Malaysia. 
 However, the question still remains of how long the immunity 
will last and whether a booster dose is necessary. 
 A study was done in 2013 investigating HBV infections among 
new students in a local university (Ng et al, 2013). The overall 
prevalence of HBsAg among 2,923 of the students was 0.62%. The 
prevalence among those born before 1989 was 1.08% and for those 
born on or after 1989 it was 0.2%. What is interesting is that only 
about 34% of the vaccinated cohort had adequate anti-HBs. Six 
students (0.4%) from the vaccinated cohort were found to have anti-
HBc, meaning that they had acquired hepatitis B infections before, 
while another three students were HBsAg positive. This study 
suggests that the universal and voluntary vaccination programme 
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in Malaysia has been effective in preventing hepatitis B and also 
that a significant proportion of vaccinated individuals did not have 
adequate seroprotection levels of anti-HBs.
 Our study aimed to evaluate the level of hepatitis B 
immunity among Malaysian undergraduate students 23 years 
after commencement of the nationwide hepatitis B childhood 
immunisation programme in Malaysia (Hudu et al, 2013a). A 
total of 402 serum samples obtained from volunteer undergraduate 
students were screened for the presence of hepatitis B surface 
antibodies using qualitative ELISA. 
 The results showed that 62.7% of the subjects had protective 
anti-hepatitis B surface antigens (>10 IU/L). The estimated post-
vaccination immunity was found to be at least 20 years, indicating 
persistent immunity against hepatitis B. Subjects with antibody 
levels of less than 10 IU/L were given a booster dose of hepatitis 
B vaccine and anamnestic response was 94.0% when they were re-
evaluated a month later. This clearly shows that the immunisation 
program has been successful and important in bringing down the 
prevalence of hepatitis B in the country.
 Despite waning antibody responses, hepatitis B vaccination is 
effective in preventing chronic HBV infections years after primary 
vaccination.
 It is believed that the immune memory cells play a very 
important role in the prevention of hepatitis B. They are likely to be 
present even after anti-HBs are no longer measurable. The immune 
memory cells accelerate anti-HBs response upon re-exposure to 
HBsAg. This is called a booster. 
 The critical issue about universal HBV vaccination is not 
whether it is effective in protecting children from HBV infections, 
but whether its protection can endure till adulthood. Booster vaccine 
dose is not recommended as a routine practice if there is adequate 
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seroprotection post-immunisation. However, it is recommended for 
adolescents and young adults with increased risk of HBV infection.
OCCULT HEPATITIS B INFECTION
Occult hepatitis B infection (OBI) is defined as the presence of HBV 
DNA in the blood or liver, absence of HBsAg, with or without anti-
HBc (Brechot et al, 2001). OBI with positive anti-HBc is known 
as seropositive OBI. In OBI infections the amount of HBV DNA 
in the blood is typically very low, therefore a sensitive detection 
method, such as PCR or real time PCR, is needed. 
 OBI has been found in patients with hepatocellular carcinoma, 
past hepatitis B infection, chronic hepatitis C or even in individuals 
without serological markers. In other words, OBI is not just 
restricted to patients with liver disease but may also be observed 
in individuals with normal liver parameters such as blood donors. 
 Occult hepatitis B infection is postulated to be a result of various 
clinical conditions, which include the incubation period of acute 
infections, the tail-end stage of chronic hepatitis B, low-level viral 
replication after recovery from hepatitis and escape mutants not 
detected by current HBsAg tests. 
 OBI attributed to mutations in the virus surface protein, HBsAg, 
is called surface mutation (Hudu et al, 2013b). 
 It is associated with flare ups of liver disease in hepatitis C 
patients who do not exhibit changes in HCV RNA levels and even 
reduces the response rate to interferon therapy. It is frequently 
detected in cryptogenic liver diseases and autoimmune hepatitis. 
Hepatitis B virus reactivation is a well-known complication in 
patients with occult infection under immune suppression, such as 
anti-cancer therapy and human immunodeficiency infection. It also 
increases the risk of hepatitis B virus transmission through blood 
transfusion.
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 The mutations on the surface protein of the hepatitis B virus 
pose challenges to available diagnostic tests. Detection of OBI thus 
requires highly sensitive tests such as PCR or real time PCR. The 
fact that a vast majority of available tests are not designed or able 
to detect OBI has implications for blood transfusion and organ 
transplants, where there can be potential transmission of the virus 
to the recipients. 
 Another circumstance of concern is vertical transmission of 
the mutated virus, which potentially occurs in countries where 
vertical transmission is the most common mode of infection. The 
concomitant administration of hepatitis B vaccine and hepatitis B 
immunoglobulin (HBIg) at birth may also pose problems whereby 
both active and passive immunisations may exert evolutional 
pressures to select mutants (Wu et al, 2010). Thus, vaccinated 
children are more likely to harbour mutations than unvaccinated 
children.
 The neutralising epitope that is of importance is a region called 
the “a” determinant, situated at amino acids 124 – 147. Antigenic 
response to this epitope will mount neutralising antibodies, anti-
HBs, which are vital to inactivate the virus and thus prevent the 
infection. Mutations in this region could lead to a conformational 
change of this epitope and therefore can affect the antigenicity 
(Ma and Wang, 2012). Several notable mutations, such as T/I126S, 
Q129H, G130N, S143L, D144A, G145A and G145R, result in 
diagnostic failure and they are thus able to escape from being 
neutralised by vaccine-induced antibodies. The exact mechanism 
of the mutation is as yet poorly understood. It is speculated that the 
hepatitis B viral DNA polymerase enzyme lacks proofreading ability 
and this makes it highly susceptible to nucleotide misincorporation 
during reverse transcription or replication. 
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 In Malaysia, mutations were observed in 11% of patients 
receiving antiviral therapy, of which, 8% carried mutants previously 
described as vaccine-associated escape mutants and another 
seven strains carried other types of mutants (Meldal et al, 2011). 
Although the introduction of a hepatitis B vaccination program 
has been effective in many countries, the emergence of anti-HBc 
in vaccinated individuals suggests the possibility of contact with 
hepatitis B virus with mutant strains subsequent to vaccination. 
These surface mutants are of enormous importance because they are 
capable of infecting both unvaccinated and vaccinated individuals. 
In other words, the whole population is at risk. 
 From a clinical point of view, establishing diagnosis through 
routine test methods will result in a significant number of cases not 
being detected. These undiagnosed cases will progress undetected 
leading to occult chronic infection, liver failure and subsequently, 
hepatocellular carcinoma. 
 We were trying to assess the OBI situation in Malaysia. An 
earlier study had reported that ten Malaysian blood donors were 
identified as having OBI (Candotti et al, 2012) but this study did not 
look into the extent of the disease. Our study aimed instead to detect 
OBI and characterise the hepatitis B virus among blood donors and 
hepatitis B vaccinees (Hudu et al, 2015). The phylogenetic analysis 
of the vaccine-escape hepatitis B strains would give an insight 
into the prevalence of the strains as well as help in the design of 
diagnostic assays to detect these mutants. 
 One thousand serum samples were collected for this study, 
where 500 samples were from blood donors from the National Blood 
Centre and another 500 samples from volunteer undergraduate 
students at Universiti Putra Malaysia. The samples were then tested 
for the presence of Hepatitis B surface antigen, antibodies and core 
antibodies  using the ELISA method. DNA detection was performed 
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via nested PCR, and the S gene was sequenced and analysed using 
bioinformatics. 
 Of the 1,000 samples that were screened, 5.5% (55/1,000) were 
found to be HBsAg-negative and anti-HBc-positive. All 55 samples 
registered positive for HBV DNA by nested PCR. A total of 84.8% 
of the samples were anti-HBs positive indicating some degree of 
protection against the virus.  Of the 55 samples that were positive 
for HBV DNA, 48 samples were positive for anti-HBs. None of 
the samples were positive for HBsAg. 
 It is interesting to note that anti-HBc can be used as a surrogate 
marker for occult hepatitis B infection. This may be useful in 
countries of limited resources where  sensitive nucleic acid testing is 
expensive and not affordable. Furthermore, detection of OBI needs 
highly sensitive nucleic acid testing (NAT) as the DNA copies can 
be really low. Thus, anti-HBc can also be used as a complementary 
test to enhance the safety of blood transfusion procedures (Hudu 
et al, 2016a)
 All of the aforementioned 55 isolates were found to belong 
to genotype B, which is also the predominant genotype reported 
in Malaysia (Figure 13). Several mutations were found across all 
the sequences, both synonymous and non-synonymous mutations, 
with the most nucleotide mutations occurring at position 342, 
where adenine was replaced by guanine and cytosine at position 46 
replaced by adenine in 96.4% and 98.0% of the isolates, respectively 
(Table 2).
47 ❘❘❚ 
Zamberi Sekawi
 
Figure 13  Phylogeny of the S gene of 35 isolates from Malaysian 
blood donors and reference strains from established genotypes (A to 
H) from the NCBI GenBank. The blue triangles indicate an aberrant 
genotype. The evolutionary relationship was inferred using the ML 
method based on the Kimura model. Malaysian isolates are indicated 
by HBV UPM D followed by the isolate number and all belong to 
genotype B, with the exception of the aberrant strains. 
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Table 2  Distribution of amino acid mutations within different regions 
of the surface protein. 
 Aligned deduced amino acid sequence showed corresponding 
mutations at various points of the amino acid sequences of the 
surface protein, including substitutions of deletions. The mutation 
at amino acid 16 was common to all Malaysian isolates, resulting 
in the substitution of glutamine (Q) with lysine (K) in 53 of the 
isolates, while the remaining two isolates contained an arginine 
residue or a stop codon. A total of 105 amino acid mutations were 
found in all 55 Malaysian isolates, 85.7% (90/105) outside the major 
hydrophilic region (MHR) and 14.3 % (15/105)  within the MHR, 
of which 40% (6/150) were within the “a” determinant region. 
  Most of the sequences were found to exhibit a close relationship 
with the reference strain from Panama, which belonged to genotype 
B, serotype adw2. Other isolates were closely related to reference 
isolates from Canada, the Philippines and Indonesia. Conversely, 
49 ❘❘❚ 
Zamberi Sekawi
sequences from vaccinated Malaysian individuals were separated 
into two clusters, the majority of which were found to have a close 
evolutionary relationship with reference isolates from China, 
Taiwan and Japan. However, some sequences from vaccinated 
individuals were distantly related to other sequences belonging to 
different clades and sub-clades, as a result of frequent mutations 
within the S gene. 
 The risk of transmitting occult hepatitis B infection depends 
on the presence of the HBV DNA copied in the plasma and the 
volume of the plasma transfused. Hence, the higher the viral load 
in the transfused blood, the higher the chance of infectivity. The 
presence of high anti-HBs in the donors’ blood also influences the 
rate of infectivity. 
 The immune status of recipients and donors also play an 
important role in determining infectivity. Recent infectivity data 
indicate a transmission rate of 3.8% (Seed and Kiely, 2013), but 
the rate is higher in unvaccinated recipients of occult hepatitis B 
blood or blood products. 
 The only reliable detection method is the detection of the 
HBV DNA by nested PCR or real-time PCR. This is because these 
two methods are highly sensitive in detecting minute amounts of 
hepatitis B DNA. A viral load of less than 200 IU/mL has been 
defined for OBI diagnosis. In more than 90% of OBI patients, the 
viral load in serum was around 20 IU/mL. A serum with more than 
200 IU/mL should be interpreted as an infection caused by escape 
mutants and not an OBI (Sara et al, 2011).
 Most OBI cases are asymptomatic and clinically not well 
defined. These cases are associated with the risk of developing 
cirrhosis and hepatocellular carcinoma. Immunosuppression may 
also lead to HBV reactivation. 
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 Hepatitis B core antibodies (anti-HBc) are detected in almost 
every patient with previous exposure to the hepatitis B virus. 
However, one cannot understand the activity of the disease based 
on this marker alone. Asymptomatic individuals with immunity, 
as a result of previous natural infection or vaccination, with the 
presence of anti-HBs are referred to as isolated anti-HBc. In our 
study, all individuals in this group of isolated anti-HBc had HBV 
DNA detected by molecular method. We are however concerned 
about the degree of protection available to individuals where the 
neutralising antibody, anti-HBs, were either undetectable or lower 
than the recommended limit of 10 IU/L. Therefore, our study aimed 
to identify the implication of an isolated hepatitis B core antibody 
and evaluate the effect of hepatitis B vaccine boosters in isolated 
anti-HBc cases, among adults who had received the HBV vaccine 
as infants. 
 A total of 408 undergraduate students who had received 
hepatitis B vaccination as infants volunteered for this study. They 
were born after 1989 when the hepatitis B childhood vaccination 
programme had been implemented and thus it was assumed that all 
of them had been given the full dose of the vaccine, as the coverage 
of hepatitis B childhood immunisation is almost 100%.  
 They were tested for the presence of Hepatitis B surface antigen, 
surface antibodies (anti-HBs) and core antibodies using ELISA. 
Molecular detection of hepatitis B viral DNA was also performed 
using nested polymerase chain reaction (Hudu et al, 2013c). 
 Slightly less than two-thirds of the volunteers (62.5%) were 
found to have adequate hepatitis B protection (anti-HBs more than 
10 IU/L). The prevalence of isolated anti-HBc was found to be 4.9% 
(20 of 408 individuals), out of which 80%  had  hepatitis B surface 
antibodies titre higher than 10 IU/L. All the 20 anti-HBc positive 
individuals had detectable hepatitis B viral DNA in their serum. 
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 The subjects with isolated anti-HBc with undesirable 
protective levels of anti-HBs were given a single booster dose of 
recombinant hepatitis B vaccine. It was good to note that there 
was 100% anamnestic response from these individuals, attaining 
high concentrations of anti-HBs a month after the booster dose 
had been administered. An absence of anamnestic response in 
those with isolated anti-HBc could indicate low-level carriers with 
immunological tolerance to surface antigens that are incapable of 
producing antibodies. However, before such a conclusion is drawn 
vaccine failure owing to improper handling and storage must first 
be ruled out. 
 In Australia, a study involving anti-HBc positive patients 
revealed a prevalence of 0.69% OBI (Martinex et al, 2015). 
They identified eight nucleotide changes in the small S protein 
and polymerase gene which were believed to have caused altered 
antigenicity and low viral replication which resulted in undetectable 
HBsAg and extremely low levels of HBV DNA in the serum. 
 An interesting study was carried out in China, looking at the 
prevalence of occult hepatitis B virus infection among individuals 
with a family history of chronic hepatitis B virus infection (Zhang 
et al, 2015). Currently,  the impact of OBI in individuals living 
with family members with the infection is still not clear. Serum 
samples were collected from 747 HBsAg-negative people with a 
family history of HBV infection and 579 HBsAg-negative volunteer 
blood donors (which acted as the control group). The prevalence 
of OBI was 8.0% (60/747) among the HBsAg-negative individuals 
with a family history of chronic HBV infection, compared to 2.6% 
(15/579) among the blood donors (p < 0.05). The prevalence of 
HBV genotype B infection was lower in the OBI group than in 
the control group (p= 0.031). The substitution rates in the major 
hydrophilic region and the “a” determinant seemed to be higher 
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in the OBI group, and stop codon mutations more frequent in the 
OBI sequences. This indicates that the S region mutations and 
the escape mechanism were not likely to be the major causes of 
increased prevalence of OBI.
 In a cross-sectional study in Iran, the prevalence of OBI among 
selected high-risk groups of children born to HBsAg-positive 
mothers was determined (Shahmoradi et al, 2012). A total of 
75 HBsAg negative children who had received full prophylactic 
coverage (vaccine and HBIG) against HBV participated in the 
study. Their sera were examined for the presence of HBV DNA. 
The sequences of the HBV genome isolated from the patients with 
OBI were then analysed and compared with the wild type HBV 
genome prevalent in Iran. 
 Twenty-eight percent of the patients were found to harbour OBI 
in the presence of adequate levels of anti-HBs, of whom only four 
showed serological evidence of past HBV exposure, as indicated 
by the presence of anti-HBc. The HBV sequences obtained from 
the analysis of the sera of the HBsAg seronegative carriers showed 
point mutations, deletions and splicing alternatives associated with 
OBI. Ten (71%) of the 14 HBV surface-positive isolates carried 
G145R, which confirmed the presence of vaccine-escaped mutants 
in the children despite full immunisation against HBV. 
 The children with OBI were further evaluated for persistence 
of the HBV DNA. Follow up was carried out for an additional 36 
months (Sadeghi et al, 2015). In the follow up tests all the children 
still tested negative for HBsAg, HBeAg and anti-HBe. Their liver 
function tests were also within the normal range. Real-time PCR 
showed that all of them were negative for HBV DNA except for 
one child. 
53 ❘❘❚ 
Zamberi Sekawi
 The only still OBI-positive patient had an HBV DNA level of 50 
copies/ml. The amino acid alignment of the whole surface protein 
showed the presence of the G145R mutation, similar to that seen 
previously. His initial and latest anti-HBs levels  were above the 
protective levels. He also persistently tested negative for anti-HBc. 
His mother, who was positive for HBsAg, had no mutations in the 
‘a’ determinant region. On follow-up, 18 months later (54 months 
after initial sampling), his samples showed that HBV DNA was 
undetectable. 
 This study clearly showed that in children, HBV DNA was 
cleared in the presence of adequate levels anti-HBs. It can be 
postulated that in high-risk children, over time, adequate levels of 
anti-HBs after vaccine and HBIg immunoprophylaxis after birth 
could eventually clear the virus. However, periodic monitoring of 
the OBI status is highly recommended. 
 The transmission of any diseases through blood transfusion is 
not acceptable by today’s standards and this issue has always been 
taken seriously. To enhance the safety of blood transfusions, rigorous 
screening methods are implemented. The current standard method 
of screening blood for hepatitis B is by nucleic acid testing for HBV 
DNA, which is highly sensitive. HBsAg mutants however pose 
diagnostic challenges, as they may not be detected using standard 
detection methods due to the alteration on the hepatitis B surface 
antigen. 
 The prevalence of occult hepatitis B infection in blood donors 
was estimated to be 8.55 per 1 million donations, according to a 
2008 international survey (Dong et al, 2015). 
 The clinical outcome of occult HBV transmission primarily 
depends on the recipient’s immune status and the number of HBV 
DNA copies present in the blood products. The presence of donor 
❚❘❘ 54
Living Dangerously in a Virus World
anti-HBs reduces the risk of HBV infection by approximately five-
folds. The risk of HBV transmission may be lower in endemic areas 
than in non-endemic areas, because most recipients would have 
already been exposed to HBV. Blood safety for HBV, including OBI, 
has substantially improved, but the possibility for OBI transmission 
still remains (Dong et al, 2015).
 There are important clinical concerns regarding OBI (Yuen 
et al, 2017). Firstly, OBI can be transmitted through blood 
products and organ transplants from donors with OBI. The risk of 
transmission thus needs to be ascertained. Secondly, we also need to 
understand the effect of OBI on the measurable parameters for liver 
disease, such as liver function, liver histologic features and long-
term complications, including liver cirrhosis and hepatocellular 
carcinoma. Thirdly, it is also important to understand whether the 
presence of OBI in patients with other chronic hepatitis diseases, 
e.g., chronic hepatitis C infection and alcoholic liver disease, would 
have additive or synergistic harmful effects on the development 
of hepatocellular carcinoma. Finally, we need to define the risk of 
HBV reactivation in OBI patients who undergo immunosuppressive 
therapy. 
 The risk of HBV chronicity depends on the age of the subjects 
when they first contract the virus. The risks of HBV chronicity are 
90%, 30% and 2% for those whose ages are <1 year, 1 to 5 years 
and >5 years old, respectively (Lai et al, 2003). This means that in 
more than 95% of adults who contract the virus it would not have 
resulted in HBV chronicity. The majority of these subjects display 
no symptoms, and develop anti-HBs and anti-HBc, during and upon 
resolution of acute infections. Some would have a typical history 
and symptoms of acute infections such as malaise, loss of appetite, 
nausea and/ or tea-coloured urine. The sequela of “acute” hepatitis 
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B is not as simple as previously believed. It is proven that HBV 
DNA is present in the serum and peripheral blood mononuclear 
cells of patients who have recovered from acute HBV infections. 
In such situations, the liver inflammation is usually mild. 
EMERGING INFECTIONS OF HEPATITIS E
The Hepatitis E virus is a tiny non-enveloped virus, 27 – 34 nm in 
diameter, with a single-stranded RNA genome. The virus belongs 
to the genus, Orthohepevirus, which is a member of the family 
Hepeviridae. It has four species (A – D) and eight genotypes   (1 – 
8). Based on seroprevalence data, it is estimated that one-third of 
the world’s population has been infected with HEV.
 HEV is excreted in the stool of infected persons and is 
transmitted by the following routes: faecal-oral; through potable 
water contamination; ingested food, from infected animals 
(raw or uncooked pig, wild boar or deer meat); zoonosis, from 
human exposure to body fluids of infected animals; transfusion 
of contaminated blood products; vertical transmission (maternal-
foetal); and transplantations with HEV-infected grafts. Of these, 
the most common is through contaminated water.
 The four prevalent genotypes are genotypes 1 through 4. 
Genotypes 1 and 2 cause outbreaks of hepatitis (Guerra et al, 2017), 
where genotype 1 is present in Asia and North Africa, and genotype 
2 in Mexico and Central Africa. They are transmitted mainly through 
contaminated water and the faecal-oral route. Genotypes 3 and 4 
are endemic, and are considered swine viruses, capable of infecting 
humans as accidental hosts. It is good to note that despite the distinct 
genotypes, cross-immunity occurs which has good implications for 
vaccine development. 
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 The incubation period of this virus is 2 to 6 weeks. The most 
common age group infected is between 15 to 40 years of age. The 
common symptoms of hepatitis E are fever, nausea, abdominal 
pain, vomiting, anorexia, malaise, jaundice and hepatomegaly. In 
most cases, it is a self-limiting disease lasting from a few days to 
weeks. In developed countries, it can cause chronic disease with 
progression to cirrhosis. However, fulminant hepatic failure can 
also result in morbidity and mortality among high-risk groups, such 
as, pregnant women, immunocompromised individuals, elderly 
people and patients with pre-existing liver diseases  such as chronic 
hepatitis B or C.
 In Japan, HEV cases were found to be directly associated with 
eating raw or undercooked deer meat, while several cases of HEV 
were epidemiologically linked to consumption of poorly cooked 
wild boar meat or pork. 
 In our study, we looked at the issue of hepatitis E virus in 
chronic hepatitis B patients. We characterised HEV by comparative 
genomic analysis to relate it to a zoonotic origin. 
 A total of 82 chronic hepatitis B patients were recruited for 
this study which spanned from May 2015 to May 2016. Serological 
and molecular investigations of HEV were conducted among these 
patients. The detected HEV were sequenced and the genomes 
and deduced amino acids were characterised using molecular 
evolutionary genetic analysis software. 
 Of the 82 chronic hepatitis B patients that were tested, 9.8% 
(8/82) were found to be HEV positive. Phylogenetic analysis of 
the eight HEV RNA sequences showed that they were of genotype 
4 (Figure 14). Homology of the Malaysian sequences, in terms of 
geographical relatedness to other Asian countries, revealed that most 
of the Malaysian isolates were closely related to reference isolates 
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from Laos, India and Thailand and one of the Malaysian isolates 
was related to isolates from Japan, Nepal and China. 
 Amino acid sequence analysis of our isolates which was 
compared to a reference swine HEV from China exhibited 99% 
similarity and showed that our isolates had 3 to 11 amino acid 
variations from the swine HEV at different positions of the gene. 
This study highlighted the fact that comparative analysis of the 
hepatitis E virus detected among the chronic hepatitis B patients 
suggests a zoonotic origin. 
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Figure 14 Hepatitis E virus genotyping by molecular phylogenetic 
analysis. The evolutionary relationship was inferred using maximum 
likelihood. The red dots indicate Malaysian isolates belonging to 
genotype 4. G1, G2, G3 and G4 indicate genotype 1, 2, 3 and 4, 
respectively. 
THE IMPORTANCE OF ADULT IMMUNISATION 
Immunisation is recognised as one of the greatest public health 
achievements. There have been huge successes among the paediatric 
population in the prevention of potentially fatal infectious diseases, 
such as measles, tetanus and whooping cough. However, this is not 
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the case for adults. Adults need protection from infectious diseases 
too and there are many vaccines available to protect them. 
 Adults need vaccines just like children. As we age, influenza 
poses significant threats of morbidity and mortality and this can 
be prevented through annual influenza vaccinations. As a result of 
the low number of vaccinees, vaccine-preventable diseases among 
adults result in a significant economic burden. Our immunity also 
wanes with age. Antibodies produced as a result of childhood 
immunisation reduce significantly over time and will no longer be 
able to protect us against the intended infectious diseases. Booster 
vaccines are thus required to maintain the antibodies at optimum 
levels.  
 Low vaccine uptake means that preventable infectious diseases 
can result in costs to individuals and society in terms of deaths, 
disabilities and economic losses from doctor visits, hospitalisations 
and loss of income. 
 In the United States, in 2015, it was estimated,  based on 
the prevailing vaccination uptake rates, that vaccine-preventable 
diseases cost individuals and society $9 billion   (~ RM40 billion) 
annually, through direct costs and productivity losses, $7.1 billion 
(~ RM30 billion) of which occurs among the unvaccinated (Ozawa 
et al, 2016). This illustrates that increasing adult immunisation 
rates can potentially reduce the annual economic burden. In 2015 
the coverage of all vaccines for adults remained low (Williams et 
al, 2017). The vaccination coverage for adults aged ≥19 years for 
influenza, pneumococcal and Tdap vaccines were 44.8%, 23.0% 
and 24.7%, respectively. However, the vaccine coverage for adults 
aged ≥65 years was significantly higher (influenza, 73.5% and 
pneumococcal, 63.6%). 
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 Adults might choose not to receive a vaccination for various 
reasons, including belief that a healthy person does not need any 
vaccines, concern about side effects, belief that the vaccine can 
cause illness, poor attitudes toward vaccines and lack of comfort 
or distrust in the government and health care system. 
 A study was done to identify the barriers to and perceptions of 
immunisations in adults of all ages (Sevin et al, 2016). The top five 
factors likely to affect the decision to receive an immunisation among 
the 304 respondents in the study were: “doctor’s recommendation” 
(80.6 %), “knowing why I should get a vaccine” (78.2 %), 
“knowing which vaccines I need” (75.5 %), “cost” (54.2 %), and 
“concern about getting sick if I get a vaccine” (54.0 %). Significant 
differences in factors influencing the immunisation decision exist 
among the respondents, based on ethnicity and education level. 
For those participants with self-identified diabetes, heart disease or 
asthma, less than half were aware that certain immunisations could 
reduce the risk of complications associated with their diseases.
 Understanding adult patients’ attitudes could assist in creating a 
more effective design and tailoring of interventions to improve adult 
vaccination uptake. In a study  determining patient perspectives 
of adult vaccines, patients expressed positive attitudes towards 
vaccines in general and were in favour of receiving reminders/ 
recall notices for adult vaccines (Albright et al, 2017). 
 In the United States, a programme called the 4 Pillars Practice 
Transformation Program, (also known as the 4 Pillars Toolkit) is 
a primary care practice improvement aid programme focused on 
changing behaviour using evidence-based strategies organised 
into four domains. The pillars are convenient vaccination services, 
communication with patients about the importance of immunisation 
and the availability of vaccines, enhanced office systems to facilitate 
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immunisation and motivation through an office immunisation 
champion who monitors progress and encourages adherence to 
vaccination-promoting office procedures to improve vaccine uptake. 
The Toolkit has been tested in several trials and was found to be 
moderately effective in increasing immunisation rates in adults 
and children. Implementing an intervention based on the 4 Pillars 
Practice Transformation Program is a cost-effective undertaking 
in primary care practices for individuals aged 65 and older, with 
predicted public health benefits (Smith et al, 2017).
 Despite guidelines for adult vaccination, there are substantial 
gaps in knowledge, attitudes and beliefs among both the public and 
healthcare providers that lead to low vaccine coverage. A systematic 
approach that involves education, elimination of barriers and 
establishing and improving infrastructure for adult immunisation 
is therefore required.
IMMUNISATIONS AMONG HEALTH CARE 
PROFESSIONALS
Health care professionals (HCP) are in constant contact with 
their patients and therefore are at risk of exposure and possible 
transmission of vaccine-preventable diseases (VCP). HCPs do not 
only refer to doctors, nurses and those working in  hospitals but also 
includes students of these professions, volunteers and administrative 
staff. To protect themselves and prevent the risk of transmission of 
hospital infections to patients, it is essential for HCPs to maintain 
immunity against VCPs. There should thus be a comprehensive 
policy, at all medical or health facilities, that requires all HCPs to 
get themselves protected via immunisations. 
❚❘❘ 62
Living Dangerously in a Virus World
 Transmission of nosocomial influenza from health care 
professionals (HCP) has been identified as an important cause of 
morbidity and mortality among patients, especially in high-risk 
groups such as the elderly, children and the immunocompromised. 
 Influenza vaccination is thus one of the highly recommended 
vaccines for HCPs to be taken annually. The aim is to reduce the 
risks of contracting influenza and influenza-like illnesses, minimise 
absenteeism,  and prevention of hospital-acquired influenza and its 
associated morbidity and mortality among their patients. 
 We carried out a cross-sectional survey at three hospitals in 
Kuala Lumpur and Selangor, to ascertain the rate of influenza 
vaccination uptake, the knowledge and attitude of HCPs regarding 
the influenza vaccine as well as the employers’ policy on encouraging 
their workers’ influenza vaccination uptake. This study is the first 
of its kind in Malaysia (Hudu et al, 2016b). 
 This survey included HCPs from both government and private 
hospitals in the Klang Valley. A total of 690 questionnaires were 
distributed and received a reasonably good response rate of 76.4% 
(527/690). Nurses and midwives constituted the majority of the 
respondents (49.3%), followed by technologists (16.7%) and 
clinicians (10.8%). Majority (80.5%) were involved in the direct 
care of patients, of which 53.1% had received the flu vaccination 
within a period of one year. 
 Of the 527 HCPs that participated in this study, 271 (51.4%) had 
been vaccinated. The highest vaccine uptakes in terms of specialty 
were internal medicine and emergency medicine. The results of this 
study also showed that a high proportion of HCPs concurred that 
influenza poses a serious threat to their health. Those HCPs who 
were vaccinated did so to protect themselves against influenza. 
A significant proportion of the HCPs had good knowledge about 
the transmission of the influenza virus as well as the signs and 
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symptoms of infection. Having said that, 49.5% believed that they 
would definitely get vaccinated the following year, 
 This study also assessed employer policies on flu vaccination 
among their employees. In this study, 31.9% of the HCPs said that 
their employers provided them with free or subsidised flu vaccine. 
It was also found that 61.9% of those that were offered influenza 
vaccination on site received the vaccine.
 This study highlighted the fact that even though HCPs had 
good knowledge on the need for the influenza vaccine and some 
employers provided the vaccine, the uptake was still low. It is worth 
looking into the reasons why this is happening.  
 There are several potential strategies to increase vaccination 
rates among HCPs that are worth considering (Ozisik et al, 2017). 
Different groups of HCPs tend to have different perceptions and 
expectations of adult vaccination and therefore have different 
motivations. Some of the motivations that can be encouraged 
are motivations of self-protection, to protect patients, free and 
accessible vaccines, previous vaccination and model colleagues. 
 Another strategy to improve vaccination rates among HCPs is to 
educate them on adult vaccination and also improvements in health 
literacy. Institutional leadership and implementation of policies play 
major roles in pushing this strategy where strong commitment and 
support are definitely needed.
CONCLUSION
Human viruses pose a constant threat to humans. Looking at the day-
to-day morbidity and mortality rates that they have caused in clinics 
and hospitals, tackling the infections will always be challenging. 
This is further worsened by the infectious nature of the diseases 
they spread. We have experienced deadly infectious diseases in the 
past, which spread rapidly across many countries in a short period 
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of time. It is thus prudent and important for doctors, scientists and 
researchers to be at the forefront to counteract these threats. A proper 
surveillance system to monitor the progress of these diseases should 
be given priority. As a whole, research is a very important tool and 
mechanism to ensure that our interventions and actions are indeed 
on the right track. To add impact  the research should ideally be 
collaborative and comprehensive in nature. Through such efforts 
at the global level, the threat from human viruses can be contained 
in a systematic and methodical manner. 
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Asian Animals: Of Buffaloes and 
Goats and Fishes Too
 10 August 1996
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36. Prof. Dr. Nazaruddin Mohd. Jali
 Will Rural Sociology Remain Relevant 
in the 21st Century?
 21 September 1996
37. Prof. Dr. Abdul Rani Bahaman
 Leptospirosis-A Model for 
Epidemiology, Diagnosis and Control 
of Infectious Diseases
 16 November 1996
38. Prof. Dr. Marziah Mahmood
 Plant Biotechnology - Strategies for 
Commercialization
 21 December 1996
39. Prof. Dr. Ishak Hj. Omar
 Market Relationships in the Malaysian 
Fish Trade: Theory and Application
 22 March 1997
40. Prof. Dr. Suhaila Mohamad
 Food and its Healing Power
 12 April 1997
41. Prof. Dr. Malay Raj Mukerjee
 A Distributed Collaborative 
Environment for Distance Learning 
Applications
 17 June 1998
42. Prof. Dr. Wong Kai Choo
 Advancing the Fruit Industry in 
Malaysia: A Need to Shift Research 
Emphasis
 15 May 1999
43. Prof. Dr. Aini Ideris
 Avian Respiratory and 
Immunosuppressive Diseases- A Fatal 
Attraction
 10 July 1999
44. Prof. Dr. Sariah Meon
 Biological Control of Plant Pathogens: 
Harnessing the Richness of Microbial 
Diversity
 14 August 1999
45. Prof. Dr. Azizah Hashim
 The Endomycorrhiza: A Futile 
Investment?
 23 October 1999
46. Prof. Dr. Noraini Abdul Samad
 Molecular Plant Virology: The Way 
Forward
 2 February 2000
47. Prof. Dr. Muhamad Awang
 Do We Have Enough Clean Air to 
Breathe?
 7 April 2000
48. Prof. Dr. Lee Chnoong Kheng
 Green Environment, Clean Power
 24 June 2000
49. Prof. Dr. Mohd. Ghazali Mohayidin
 Managing Change in the Agriculture 
Sector: The Need for Innovative 
Educational Initiatives
 12 January 2002
50. Prof. Dr. Fatimah Mohd. Arshad
 Analisis Pemasaran Pertanian 
di Malaysia: Keperluan Agenda 
Pembaharuan
 26 January 2002
51. Prof. Dr. Nik Mustapha R. Abdullah
 Fisheries Co-Management: An 
Institutional Innovation Towards 
Sustainable Fisheries Industry
 28 February 2002
52. Prof. Dr. Gulam Rusul Rahmat Ali
 Food Safety: Perspectives and 
Challenges
 23 March 2002
53. Prof. Dr. Zaharah A. Rahman
 Nutrient Management Strategies for 
Sustainable Crop Production in Acid 
Soils: The Role of Research Using 
Isotopes
 13 April 2002
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54. Prof. Dr. Maisom Abdullah
 Productivity Driven Growth: Problems 
& Possibilities
 27 April 2002
55. Prof. Dr. Wan Omar Abdullah
 Immunodiagnosis and Vaccination for 
Brugian Filariasis: Direct Rewards 
from Research Investments
 6 June 2002
56. Prof. Dr. Syed Tajuddin Syed Hassan
 Agro-ento Bioinformation: Towards 
the Edge of Reality
 22 June 2002
57. Prof. Dr. Dahlan Ismail
 Sustainability of Tropical Animal-
Agricultural Production Systems: 
Integration of Dynamic Complex 
Systems
 27 June 2002
58. Prof. Dr. Ahmad Zubaidi 
Baharumshah
 The Economics of Exchange Rates in 
the East Asian Countries
 26 October 2002
59. Prof. Dr. Shaik Md. Noor Alam S.M. 
Hussain
 Contractual Justice in Asean: A 
Comparative View of Coercion
 31 October 2002
60. Prof. Dr. Wan Md. Zin Wan Yunus
 Chemical Modification of Polymers: 
Current and Future Routes for 
Synthesizing New Polymeric 
Compounds
 9 November 2002
61. Prof. Dr. Annuar Md. Nassir
 Is the KLSE Efficient? Efficient Market 
Hypothesis vs Behavioural Finance
 23 November 2002
62. Prof. Ir. Dr. Radin Umar Radin Sohadi
 Road Safety Interventions in Malaysia: 
How Effective Are They?
 21 February 2003
63. Prof. Dr. Shamsher Mohamad
 The New Shares Market: Regulatory 
Intervention, Forecast Errors and 
Challenges
 26 April 2003
64. Prof. Dr. Han Chun Kwong
 Blueprint for Transformation or 
Business as Usual? A Structurational 
Perspective of the Knowledge-Based 
Economy in Malaysia
 31 May 2003
65. Prof. Dr. Mawardi Rahmani
 Chemical Diversity of Malaysian 
Flora: Potential Source of Rich 
Therapeutic Chemicals
 26 July 2003
66. Prof. Dr. Fatimah Md. Yusoff
 An Ecological Approach: A Viable 
Option for Aquaculture Industry in 
Malaysia
 9 August 2003
67. Prof. Dr. Mohamed Ali Rajion
 The Essential Fatty Acids-Revisited
 23 August 2003
68. Prof. Dr. Azhar Md. Zain
 Psychotheraphy for Rural Malays - 
Does it Work?
 13 September 2003
69. Prof. Dr. Mohd. Zamri Saad
 Respiratory Tract Infection: 
Establishment and Control
 27 September 2003
70. Prof. Dr. Jinap Selamat
 Cocoa-Wonders for Chocolate Lovers
 14 February 2004
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71. Prof. Dr. Abdul Halim Shaari
 High Temperature Superconductivity: 
Puzzle & Promises
 13 March 2004
72. Prof. Dr. Yaakob Che Man
 Oils and Fats Analysis - Recent 
Advances and Future Prospects
 27 March 2004
73. Prof. Dr. Kaida Khalid
 Microwave Aquametry: A Growing 
Technology
 24 April 2004
74. Prof. Dr. Hasanah Mohd. Ghazali
 Tapping the Power of Enzymes- 
Greening the Food Industry
 11 May 2004
75. Prof. Dr. Yusof Ibrahim
 The Spider Mite Saga: Quest for 
Biorational Management Strategies
 22 May 2004
76. Prof. Datin Dr. Sharifah Md. Nor
 The Education of At-Risk Children: 
The Challenges Ahead
 26 June 2004
77. Prof. Dr. Ir. Wan Ishak Wan Ismail
 Agricultural Robot: A New Technology 
Development for Agro-Based Industry
 14 August 2004
78. Prof. Dr. Ahmad Said Sajap
 Insect Diseases: Resources for 
Biopesticide Development
 28 August 2004
79. Prof. Dr. Aminah Ahmad
 The Interface of Work and Family 
Roles: A Quest for Balanced Lives
 11 March 2005
80. Prof. Dr. Abdul Razak Alimon
 Challenges in Feeding Livestock: 
From Wastes to Feed
 23 April 2005
81. Prof. Dr. Haji Azimi Hj. Hamzah
 Helping Malaysian Youth Move 
Forward: Unleashing the Prime 
Enablers
 29 April 2005
82. Prof. Dr. Rasedee Abdullah
 In Search of an Early Indicator of 
Kidney Disease
 27 May 2005
83. Prof. Dr. Zulkifli Hj. Shamsuddin
 Smart Partnership: Plant-
Rhizobacteria Associations
 17 June 2005
84. Prof. Dr. Mohd Khanif  Yusop
 From the Soil to the Table
 1 July 2005
85. Prof. Dr. Annuar Kassim
 Materials Science and Technology: 
Past, Present and the Future
 8 July 2005
86. Prof. Dr. Othman Mohamed
 Enhancing Career Development 
Counselling and the Beauty of Career 
Games
 12 August 2005
87. Prof. Ir. Dr. Mohd Amin Mohd Soom
 Engineering Agricultural Water 
Management Towards Precision 
Framing
 26 August 2005
88. Prof. Dr. Mohd Arif Syed
 Bioremediation-A Hope Yet for the 
Environment?
 9 September 2005
89. Prof.  Dr. Abdul Hamid Abdul Rashid
 The Wonder of Our Neuromotor 
System and the Technological 
Challenges They Pose
 23 December 2005
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90. Prof. Dr. Norhani Abdullah
 Rumen Microbes and Some of Their 
Biotechnological Applications
 27 January 2006
91. Prof. Dr. Abdul Aziz Saharee
 Haemorrhagic Septicaemia in Cattle 
and Buffaloes: Are We Ready for 
Freedom?
 24 February 2006
92. Prof. Dr. Kamariah Abu Bakar
 Activating Teachers’ Knowledge and 
Lifelong Journey in Their Professional 
Development
 3 March 2006
93. Prof. Dr. Borhanuddin Mohd. Ali
 Internet Unwired
 24 March 2006
94. Prof. Dr. Sundararajan Thilagar
 Development and Innovation in the 
Fracture Management of Animals
 31 March 2006
95. Prof. Dr. Zainal Aznam Md. Jelan
 Strategic Feeding for a Sustainable 
Ruminant Farming
 19 May 2006
96. Prof. Dr. Mahiran Basri
 Green Organic Chemistry: Enzyme at 
Work
 14 July 2006
97. Prof. Dr. Malik Hj. Abu Hassan
 Towards Large Scale Unconstrained 
Optimization
 20 April 2007
98. Prof. Dr. Khalid Abdul Rahim
 Trade and  Sustainable Development: 
Lessons from Malaysia’s Experience
 22 June 2007
99. Prof. Dr. Mad Nasir Shamsudin
 Econometric Modelling for 
Agricultural Policy Analysis and 
Forecasting:  Between Theory and 
Reality
 13 July 2007
100. Prof. Dr. Zainal Abidin Mohamed
 Managing Change - The Fads 
and The Realities:  A Look at 
Process Reengineering, Knowledge 
Management and Blue Ocean 
Strategy 
 9 November 2007
101. Prof. Ir. Dr. Mohamed Daud
 Expert Systems for Environmental 
Impacts and Ecotourism Assessments 
 23 November 2007
102. Prof. Dr. Saleha Abdul Aziz
 Pathogens and Residues;  How Safe 
is Our Meat?
 30 November 2007
103. Prof. Dr. Jayum A. Jawan
 Hubungan Sesama Manusia
 7 December 2007
104. Prof. Dr. Zakariah Abdul Rashid
 Planning for Equal Income 
Distribution in Malaysia:  A General 
Equilibrium Approach
 28 December 2007
105. Prof. Datin Paduka Dr. Khatijah 
Yusoff
 Newcastle Disease virus: A Journey 
from Poultry to Cancer
 11 January 2008
106. Prof. Dr. Dzulkefly Kuang Abdullah
 Palm Oil: Still the Best Choice
 1 February 2008
107. Prof. Dr. Elias Saion
 Probing the Microscopic Worlds by 
Lonizing Radiation
 22 February 2008
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108. Prof. Dr. Mohd Ali Hassan
 Waste-to-Wealth Through 
Biotechnology: For Profit, People 
and Planet
 28 March 2008
109. Prof. Dr. Mohd Maarof H. A. Moksin
 Metrology at Nanoscale: Thermal 
Wave Probe Made It Simple
 11 April 2008
110. Prof. Dr. Dzolkhifli Omar
 The Future of Pesticides Technology 
in Agriculture: Maximum Target Kill 
with Minimum Collateral Damage
 25 April 2008 
111. Prof. Dr. Mohd. Yazid Abd. Manap
 Probiotics: Your Friendly Gut 
Bacteria
 9 May 2008
112. Prof. Dr. Hamami Sahri
 Sustainable Supply of  Wood and 
Fibre: Does Malaysia have Enough?
 23 May 2008
113. Prof. Dato’ Dr. Makhdzir Mardan
 Connecting the Bee Dots
 20 June 2008
114. Prof. Dr. Maimunah Ismail
 Gender & Career: Realities and 
Challenges
 25 July 2008
115. Prof. Dr. Nor Aripin Shamaan
 Biochemistry of Xenobiotics: 
Towards a Healthy Lifestyle and Safe 
Environment
 1 August 2008
116. Prof. Dr. Mohd Yunus Abdullah
 Penjagaan Kesihatan Primer di 
Malaysia:  Cabaran Prospek dan 
Implikasi dalam Latihan dan 
Penyelidikan Perubatan serta 
Sains Kesihatan di Universiti Putra 
Malaysia
 8 August 2008
117. Prof. Dr. Musa Abu Hassan
 Memanfaatkan Teknologi Maklumat 
& Komunikasi ICT untuk Semua
 15 August 2008
118. Prof. Dr. Md. Salleh Hj. Hassan
 Role of Media in Development:  
Strategies, Issues & Challenges
 22 August 2008
119. Prof. Dr. Jariah Masud
 Gender in Everyday Life
 10 October 2008
120 Prof. Dr. Mohd Shahwahid Haji 
Othman
 Mainstreaming Environment: 
Incorporating Economic Valuation 
and Market-Based Instruments in 
Decision Making
 24 October 2008
121. Prof. Dr. Son Radu
 Big Questions Small Worlds: 
Following Diverse Vistas
 31 October 2008
122. Prof. Dr. Russly Abdul Rahman
 Responding to Changing Lifestyles: 
Engineering the Convenience Foods 
28 November 2008
123. Prof. Dr. Mustafa Kamal Mohd 
Shariff
 Aesthetics in the Environment an 
Exploration of Environmental: 
Perception Through Landscape 
Preference
 9 January 2009
124. Prof. Dr. Abu Daud Silong
 Leadership Theories, Research 
& Practices:  Farming Future 
Leadership Thinking
 16 January 2009
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125. Prof. Dr. Azni Idris
 Waste Management, What is the 
Choice: Land Disposal or Biofuel?
 23 January 2009
126. Prof. Dr. Jamilah Bakar
 Freshwater  Fish: The Overlooked 
Alternative
 30 January 2009
127. Prof. Dr. Mohd. Zobir Hussein
 The Chemistry of Nanomaterial and 
Nanobiomaterial
 6 February 2009
128. Prof. Ir. Dr. Lee Teang Shui
 Engineering Agricultural: Water 
Resources
 20 February 2009
129. Prof. Dr. Ghizan Saleh
 Crop Breeding: Exploiting Genes for 
Food and Feed
 6 March 2009
130. Prof. Dr. Muzafar Shah Habibullah
 Money Demand
 27 March 2009
131.  Prof. Dr. Karen Anne Crouse
 In Search of Small Active Molecules
 3 April 2009
132. Prof. Dr. Turiman Suandi
 Volunteerism: Expanding the 
Frontiers of Youth Development
 17 April 2009
133. Prof. Dr. Arbakariya Ariff
 Industrializing Biotechnology: Roles 
of Fermentation and Bioprocess 
Technology
 8 May 2009
134. Prof. Ir. Dr. Desa Ahmad
 Mechanics of  Tillage Implements
 12 June 2009
135. Prof. Dr. W. Mahmood Mat Yunus
 Photothermal and Photoacoustic: 
From Basic Research to Industrial 
Applications
 10 July 2009
136. Prof. Dr. Taufiq Yap Yun Hin
 Catalysis for a Sustainable World
 7 August 2009
137 Prof. Dr. Raja Noor Zaliha Raja 
Abd. Rahman
 Microbial Enzymes: From Earth to 
Space
 9 October 2009
138 Prof. Ir. Dr. Barkawi Sahari 
 Materials, Energy and CNGDI 
Vehicle Engineering
 6 November 2009
139. Prof. Dr. Zulkifli Idrus
 Poultry Welfare in Modern 
Agriculture: Opportunity or Threat?
 13 November 2009
140. Prof. Dr. Mohamed Hanafi Musa
 Managing Phosphorus: Under Acid 
Soils Environment
 8 January 2010
141. Prof. Dr. Abdul Manan Mat Jais
 Haruan Channa striatus a Drug 
Discovery in an Agro-Industry 
Setting
 12 March 2010
142. Prof. Dr. Bujang Bin Kim Huat
 Problematic Soils:  In Search for 
Solution
 19 March 2010
143. Prof. Dr. Samsinar Md Sidin
 Family Purchase Decision Making:  
Current Issues & Future Challenges
 16 April 2010
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144. Prof. Dr. Mohd Adzir Mahdi
 Lightspeed:  Catch Me If  You Can
 4 June 2010
145. Prof. Dr. Raha Hj. Abdul Rahim
 Designer Genes: Fashioning Mission 
Purposed Microbes
 18 June 2010
146. Prof. Dr. Hj. Hamidon Hj. Basri
 A Stroke of Hope, A New Beginning
 2 July 2010
147. Prof. Dr. Hj. Kamaruzaman Jusoff
 Going Hyperspectral: The "Unseen" 
Captured?
 16 July 2010
148. Prof. Dr. Mohd Sapuan Salit
 Concurrent Engineering for 
Composites
 30 July 2010
149. Prof. Dr. Shattri Mansor
 Google the Earth: What's Next?
 15 October 2010
150. Prof. Dr. Mohd Basyaruddin Abdul 
Rahman
 Haute Couture: Molecules & 
Biocatalysts
 29 October 2010
151. Prof. Dr. Mohd. Hair Bejo
 Poultry Vaccines:  An Innovation for 
Food Safety and Security
 12 November 2010
152. Prof. Dr. Umi Kalsom Yusuf
 Fern of Malaysian Rain Forest
 3 December 2010
153. Prof. Dr. Ab. Rahim Bakar
 Preparing Malaysian Youths for the 
World of Work: Roles of Technical 
 and Vocational Education and 
Training (TVET)
 14 January 2011
154. Prof. Dr. Seow Heng Fong
 Are there "Magic Bullets" for 
Cancer Therapy?
 11 February 2011
155. Prof. Dr. Mohd Azmi Mohd Lila
  Biopharmaceuticals: Protection,  
 Cure and the Real Winner
  18 February 2011
156. Prof. Dr. Siti Shapor Siraj
 Genetic Manipulation in Farmed 
Fish: Enhancing Aquaculture 
Production
 25 March 2011
157. Prof. Dr. Ahmad Ismail
 Coastal Biodiversity and Pollution: 
A Continuous Conflict
 22 April 2011
158. Prof. Ir. Dr. Norman Mariun
 Energy Crisis 2050? Global 
Scenario and Way Forward for 
Malaysia
 10 June 2011
159. Prof. Dr. Mohd Razi Ismail
 Managing Plant Under Stress: A 
Challenge for Food Security
 15 July 2011
160. Prof. Dr. Patimah Ismail
 Does Genetic Polymorphisms Affect 
Health?
 23 September 2011
161.  Prof. Dr. Sidek Ab. Aziz
 Wonders of Glass: Synthesis, 
Elasticity and Application
 7 October 2011
162. Prof. Dr. Azizah Osman
 Fruits: Nutritious, Colourful, Yet 
Fragile Gifts of Nature
 14 October 2011
❚❘❘ 88
Living Dangerously in a Virus World
163. Prof. Dr. Mohd. Fauzi Ramlan
 Climate Change: Crop Performance 
and Potential
 11 November 2011
164. Prof. Dr. Adem Kiliçman
 Mathematical Modeling with 
Generalized Function
 25 November 2011
165. Prof. Dr. Fauziah Othman
 My Small World: In Biomedical 
Research
 23 December 2011
166. Prof. Dr. Japar Sidik Bujang
 The Marine Angiosperms, Seagrass
 23 March 2012
167. Prof. Dr. Zailina Hashim
 Air Quality and Children's 
Environmental Health: Is Our 
Future Generation at Risk?
 30 March 2012
168. Prof. Dr. Zainal Abidin Mohamed
 Where is the Beef? Vantage Point 
form the Livestock Supply Chain
 27 April 2012
169. Prof. Dr. Jothi Malar Panandam
 Genetic Characterisation of Animal 
Genetic Resources for Sustaninable 
Utilisation and Development
 30 November 2012
170. Prof. Dr. Fatimah Abu Bakar
 The Good The Bad & Ugly of Food 
Safety: From Molecules to Microbes
 7 December 2012
171.  Prof. Dr. Abdul Jalil Nordin
 My Colourful Sketches from Scratch: 
Molecular Imaging
 5 April 2013
172. Prof. Dr. Norlijah Othman
 Lower Respiratory Infections in 
Children: New Pathogens, Old 
Pathogens and the Way Forward
 19 April 2013
173. Prof. Dr. Jayakaran Mukundan
 Steroid-like Prescriptions English 
Language Teaching Can Ill-afford 
26 April 2013
174. Prof. Dr. Azmi Zakaria
 Photothermals Affect Our Lives
 7 June 2013
175.  Prof. Dr. Rahinah Ibrahim
 Design Informatics
 21 June 2013
176.  Prof. Dr. Gwendoline Ee Cheng
 Natural Products from Malaysian 
Rainforests
 1 November 2013
177.  Prof. Dr. Noor Akma Ibrahim
 The Many Facets of Statistical 
Modeling
 22 November 2013
178.  Prof. Dr. Paridah Md. Tahir
 Bonding with Natural Fibres
 6 December 2013
179. Prof. Dr. Abd. Wahid Haron
 Livestock Breeding: The Past, The 
Present and The Future
 9 December 2013
180.  Prof. Dr. Aziz Arshad
 Exploring Biodiversity & Fisheries 
Biology: A Fundamental Knowledge 
for Sustainabale Fish Production
 24 January 2014
181.  Prof. Dr. Mohd Mansor Ismail
 Competitiveness of Beekeeping 
Industry in Malaysia
 21 March 2014
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182. Prof. Dato' Dr. Tai Shzee Yew
 Food and Wealth from the Seas: 
Health Check for the Marine 
Fisheries of Malaysia
 25 April 2014
183.  Prof. Datin Dr. Rosenani Abu Bakar
 Waste to Health: Organic Waste 
Management for Sustainable Soil 
Management and Crop Production
 9 May 2014
184.  Prof. Dr. Abdul Rahman Omar
 Poultry Viruses: From Threat to 
Therapy
 23 May 2014
185. Prof. Dr. Mohamad Pauzi Zakaria
 Tracing the Untraceable: 
Fingerprinting Pollutants through 
Environmental Forensics
 13 June 2014
186. Prof. Dr. -Ing. Ir. Renuganth 
Varatharajoo
 Space System Trade-offs: Towards 
Spacecraft Synergisms
 15 August 2014
187. Prof. Dr. Latiffah A. Latiff
 Tranformasi Kesihatan Wanita ke 
Arah Kesejahteraan Komuniti 
7 November 2014
188. Prof. Dr. Tan Chin Ping
 Fat and Oils for a Healthier Future:
 Makro, Micro and Nanoscales
 21 November 2014
189.  Prof. Dr. Suraini Abd. Aziz
 Lignocellulosic Biofuel: A Way 
Forward
 28 November 2014
190.  Prof. Dr. Robiah Yunus
 Biobased Lubricants: Harnessing 
the Richness of Agriculture 
Resources
 30 January 2015
191.  Prof. Dr. Khozirah Shaari
 Discovering Future Cures from 
Phytochemistry to Metabolomics
 13 February 2015
192. Prof. Dr. Tengku Aizan Tengku Abdul 
Hamid
 Population Ageing in Malaysia: A 
Mosaic of Issues, Challenges and 
Prospects
 13 March 2015
193. Prof. Datin Dr. Faridah Hanum 
Ibrahim
 Forest Biodiversity: Importance of 
Species Composition Studies
 27 March 2015
194. Prof. Dr. Mohd Salleh Kamarudin 
Feeding & Nutritional Requirements 
of Young Fish
 10 April 2015
195. Prof. Dato' Dr. Mohammad Shatar 
Sabran
 Money Boy: Masalah Sosial Era 
Generasi Y
 8 Mei 2015
196. Prof. Dr. Aida Suraya Md. Yunus
 Developing Students' Mathematical 
Thinking: How Far Have We Come?
 5 June 2015
197. Prof. Dr. Amin Ismail
 Malaysian  Cocoa or Chocolates: A 
Story of Antioxidants and More...
 14 August 2015
198. Prof. Dr. Shamsuddin Sulaiman
 Casting Technology: Sustainable 
Metal Forming Process
 21 August 2015
199. Prof. Dr. Rozita Rosli
 Journey into Genetic: Taking the 
Twists and Turns of Life
 23 October 2015
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200. Prof. Dr. Nor Aini Ab Shukor
 The Un(Straight) Truth About Trees
 6 November 2015
201. Prof. Dato' Dr. Ir Mohd Saleh Jaafar
 Advancing Concrete Materials and 
Systems: The Search Continues
 13 November 2015
202. Prof. Dr. Maznah Ismail
 Germinated Brown Rice and 
Bioactive Rich Fractions: On 
Going Journey form R&D to 
Commercialisation
 29 April 2016
203. Prof. Dr. Habshah Midi
 Amazing Journey to Robust Statistics 
Discovering Outliers for Efficient 
Prediction
 6 May 2016
204. Prof. Dr. Mansor Ahmad @ Ayob 
 Going Green with 
Bionanocomposites
 27 May 2016
205. Prof. Dr. Fudziah Ismail
 Exploring Efficient Numerical Methods 
for Differental Equations
 23 September 2016
206. Prof. Dr.  Noordin Mohamed Mustapha
 Meandering Through the Superb 
Scientific World of Pathology: Exploring 
Intrapolations
 30 September 2016
207. Prof. Dr. Mohd. Majid Konting
 Teaching for Quality Learning: A 
Leadership Challenge
 21 October 2016
208. Prof. Dr. Ezhar Tamam
 Are University Students Getting Enough 
Interethnic Communication and 
Diversity Engagement Experiences? 
Concerns and Considerations
 11 November 2016
209. Prof. Dr. Bahaman Abu Samah
 Enhancing Extension Research using 
Structural Equation Modeling
 18 November 2016
210. Prof. Dr. Wen Siang Tan
 Fighting the Hepatitis B Virus: Past, 
Present  & Future
 9 December 2016
211. Prof. Dr. Mahmud Tengku Muda 
Mohamed
 Postharvest: An Unsung Solution for 
Food Security
 20 January 2017
212. Prof. Dr. Sherina Mohd Sidik
 Mental Health in the Community-
Malaysia: A 20-Year Journey of a Family 
Medicine Consultant
 27 January 2017
213. Prof. Dr. Zaidon Ashaari
 Low Density Wood: From Poor to 
Excellent
 10 Februari 2017
214. Prof. Ir. Dr. Mohd Zainal Ab. Kadir
 Lightning: A Bolt from the Blue
 17 February 2017
215. Prof. Datin Dr. Rozi Mahmud
 No Less Than a Women:  Improving 
Breast Cancer Detection and Diagnosis
 17 Mac 2017
216. Prof. Dr. Jegatheswaran Ratnasingam
 The Malaysian Furniture Industry: 
Charting its Growth Potential
 7 April 2017
217. Prof. Dr. Loh Teck Chewn
 Animal Feed: The Way Forward 
 21  April 2017
218. Prof. Dr. Luqman Chuah Abdullah
 Rigid Ceramic Filters: Numerical 
Simulation of The Pressure & Velocity 
Distributions
 5 May 2017
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219. Prof. Dr. Lai Oi Ming
 Diacylglycerols: Healty Fats of the 
Future
 19 May 2017
220. Prof. Dr. Rozumah Baharudin
 Parenting: What Matters Most?
 25 May 2017
221. Prof. Dr. Laily Paim
 Kemiskinan & Kerentaan: Penelitian 
Konsep dan Pengukuran dalam Era 
Revolusi Indsutri 4.0
 20 Oktober 2017
222. Prof. Dr. Shuhaimi Mustafa
 Halal Food Authenticity: Does it Matter 
to You?
 25 November 2017
223. Prof. Dr. Che Fauziah Ishak
 Solid Waste Management: Land 
Application of Agricultural and 
Industrial by Products
 9 Mac 2018
224.  Prof. Dr. Manohar Arumugam 
 Repair, Reconstruction, Replacement 
and Reduction of Musculoskeletal 
Disorders & Limb Injuries
 16 Mac 2018 
225. Prof. Dr. Sidek Mohd Noah
 Aplikasi Ujian Psikometrik dalam 
Bimbingan dan Kaunseling Kerjaya: 
Sejauh Mana Impaknya?
 13 April 2018
